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Fig. i. The lateral flow device developed at BAM
Writing the thesis has been like brewing an espresso: a huge amount of material, experiments, and        
discussions have had to be concentrated down to produce an easy-to-consume final shot.
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Die Ereignisse des Jahres 2020 haben uns gezeigt, wie wichtig schnelle, benutzerfreundliche und 
kostengünstige Hilfsmittel zur Gesundheitsüberwachung sind. Aus den Erfahrungen mit der be-
rüchtigten COVID-19-Pandemie wurde deutlich, dass die Verfügbarkeit eines Schnelltests das 
Schlüsselelement für ein zuverlässiges und robustes Gesundheitssystem ist. Diese einfache Tech-
nologie kann dazu beitragen, die Unsicherheit in den verschiedenen und manchmal sehr kontro-
versen statistischen Kennzahlen, mit denen das Gesundheitssystem in Zeiten einer Pandemie um-
gehen muss, erheblich zu verringern. Wenn es in Bezug auf COVID-19 möglich ist, eine große 
Anzahl von Menschen schnell und zuverlässig zu testen, würde dies den Druck auf das Gesund-
heitssystem verringern und gleichzeitig die störenden Auswirkungen der Pandemie auf Wirtschaft 
und Gesellschaft abschwächen. 
Immunoassays wie LFIA, FPIA und ELISA (Lateral Flow Immunoassay, Fluoreszenzpolarisati-
onsimmunoassay und Enzymimmunoassay) sind in vielen wichtigen Bereichen, wie der Diagnose 
von Krankheiten, der pharmazeutischen Industrie und der Umweltanalyse weit verbreitet. Die Ver-
wendung von LFIA für ein schnelles Screening vor Ort bietet beispielsweise eine einfache und 
kostengünstige Alternative zu teuren, mühsamen und zeitaufwendigen instrumentellen Methoden 
und auch zu den komplizierteren Immunoassay-Formaten. Die Ergebnisse des LFIA können in-
nerhalb von 10 bis 15 Minuten erhalten werden. Solche Verfahren, bei denen Membranen als feste 
Träger verwendet werden, haben sich als sehr vielversprechende Formate erwiesen und ermögli-
chen die Durchführung paralleler Assays in derselben Probe. In dieser Arbeit wurden Latex-Mik-
ropartikel-basierte und Gold-Nanopartikel-basierte LFIA zum schnellen Nachweis von Bisphenol 
A (BPA) entwickelt. Ein Ziel dieser Arbeit war die Suche nach geeigneten Nitrocellulose-Memb-
ranen, Konjugatpads, Membranbehandlungen sowie nach einer geeigneten LFIA-Vorbehandlung 
zur Optimierung der Leistungseigenschaften des Assays. Die Ergebnisse eines LFIA-Tests können 
sowohl mit bloßem Auge als auch instrumentell interpretiert werden. Die visuellen Nachweisgren-
zen (vLOD) wurden bei 10 μg/L gefunden. Die berechnete Nachweisgrenze (cLOD) der instru-
mentellen Auslesung betrug 0,14 μg/L. Die Synthese der erforderlichen Haptenproteinkonjugate 
und deren weitere Bewertung in einem ELISA-Aufbau führte zu einem hochempfindlichen Assay 
mit einer Nachweisgrenze von 0,05 μg/L. Eine zusätzliche Methode, der Mix-and-Read-FPIA zur 
Bestimmung von BPA, wurde entwickelt, und die Ergebnisse dieser Methode konnten innerhalb 
von 20 bis 30 Minuten erhalten werden. In dieser Studie wurden neue Tracer-Moleküle mit unter-
schiedlichen Strukturen synthetisiert, welche Fluorophore mit Derivaten des Analyten verbinden, 
einschließlich eines C6-Spacers (Ahx). Der Einfluss der Ahx-Tracer-Brückenlänge auf die Assay-
Empfindlichkeit wurde abgeschätzt. Die niedrigste Nachweisgrenze lag bei 1,0 μg/L mit einem 
Arbeitsbereich von 2 bis 155 μg/L.  
Die Methoden wurden für reale Proben gegen LC-MS/MS als Referenzmethode mit guter Über-




The events of the year 2020 have shown us the importance of fast, easy-to-use, and affordable 
health-tracking devices. From the experience with the notorious COVID-19 pandemic it became 
obvious that the availability of a rapid test is the key element for a reliable and robust healthcare 
system. This in fact simple technology can significantly reduce the uncertainty in the various and 
sometimes highly controversial statistical figures the healthcare system has to manage in times of 
a pandemic. With respect to COVID-19, if it is possible to test a large number of people quickly 
and in a reliable way, it would lift the pressure from the healthcare system and at the same time 
mitigate disruptive effects by the pandemic on the economic and social system.  
Immunoassays, like LFIA, FPIA and ELISA (lateral flow immunoassay, fluorescence polarization 
immunoassay, enzyme immunoassay), have been widely used in many important fields, such as 
diagnosis of diseases, pharmaceutical industries, and environmental analysis. The use of LFIA for 
rapid on-site screening, for example, provides a simple and low-cost alternative to expensive, la-
borious, and time-consuming instrumental methods and also to the more sophisticated immunoas-
say formats. The results from LFIA can be obtained within 10 to 15 min. Such methods, which use 
membranes as solid supports, have proven to be very promising formats and allow parallel assays 
to be performed in the same sample. In this work, latex microparticles-based and gold nanoparti-
cles-based LFIA for a rapid detection of bisphenol A (BPA) were developed. The work was fo-
cused on the search for suitable nitrocellulose membranes, conjugate pads, membrane treatments, 
as well as for a proper LFIA pre-treatment to optimize the performance properties of the assay. 
The results of an LFIA test can be interpreted both by naked eye and instrumentally. The visual 
limit of detection (vLOD) was found to be 10 μg/L. The calculated instrumental limit of detection 
(cLOD) was 0.14 μg/L. The synthesis of the required hapten-protein conjugates and further eval-
uation in an ELISA setup resulted in a highly sensitive assay with a limit of detection of 0.05 μg/L. 
An additional method, the mix-and-read FPIA for determination of BPA, was developed and re-
sults from this method could be obtained within 20 to 30 min. In this study, new tracer molecules 
with different structures that link fluorophores to derivatives of the analyte, were synthesized, in-
cluding a C6 spacer (Ahx). The influence of the Ahx tracer bridge length on the assay sensitivity 
was estimated. The lowest limit of detection was 1.0 μg/L with a working range from 2 to 155 
μg/L.  
The methods were validated for real samples against LC-MS/MS as reference method with good 
agreement with LFIA, FPIA, and ELISA. 
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 ABBREVIATIONS AND ACRONYMS 
A  
A Parameter A of the sigmoidal curve, representing the maximum signal intensity 
Ab  Antibody 
Ag Antigen 
Ahx (C6) 6-Aminohexanoic acid 
AMF 4-Aminomethylfluorescein 
B  





BPB Bisphenol B 
BPF Bisphenol F 
BPS Bisphenol S 
BSA 
BVA 
Bovine serum albumin 
Bisphenol valeric acid 
C  
C                     Parameter C of the sigmoidal curve, inflection point (in concentration units)   
CAS  Chemical abstracts service 
CR Cross-reactivity 
CV Coefficient of variation 
D  
D Parameter D of the sigmoidal curve, representing the minimal signal intensity 
DCC Dicyclohexylcarbodiimide 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
E  
EDC  N-(3-Dimethylaminopropyl)-Nʹ-ethylcarbodiimide hydrochloride 
ELISA  Enzyme-linked immunosorbent assay 
EDTA Ethylenediaminetetraacetic acid 
F  
FDA  (U.S.) Food and Drug Administration 
FPIA Fluorescence polarization immunoassay 
G  
GC-MS Gas chromatography-mass spectrometry 
GNP Gold nanoparticles  
H  




IC50 Inhibition concentration. Concentration that is required for 50 % inhibition in 
vitro (analyte concentration at the half maximum signal intensity)  
IgG  Immunoglobulin G 
L  
LF  Lateral flow 
LC-MS/MS  Liquid chromatography-tandem mass spectrometry 
LFA  Lateral flow assay 




Limit of detection 
M  
MAb Monoclonal antibody 
MALDI Matrix-assisted laser desorption/ionisation 
MRL Maximum residue level 
N  
NHS  N-hydroxysuccinimide 
O  
OD Optical density 
P  
PAb Polyclonal antibody 
PBS Phosphate buffered saline 
R  
R2 Coefficient of determination 
rpm Revolutions per minute 
RT Room temperature, 20 °C  
  
S  
SD Standard deviation 















The rapid increase in global population has accelerated the production of food, industrial products, 
and also the need for service activities. This has, in turn, contributed to the massive growth of the 
corresponding industrial sectors to meet the high demand for goods of all kind. Another effect is 
that the number of chemicals used in consumer products is steadily increasing, whereas under-
standing of their exposure pathways and associated human health risks often lag behind. Numerous 
studies on exposure to those chemicals have proven adverse health effects both on humans and 
animals. Some of the substances used in plastics production show effects on the hormone system 
and are therefore suspected to contribute to various diseases.  
One of the most important chemicals used in the production of polycarbonate plastics and epoxy 
resins is bisphenol A. The substance was first synthesized in the late-nineteenth century by the 
Russian Aleksandr Pavlovich Dianin and it came into wider use in 1905 by Theodor Zincke from 
Marburg University, Germany. Today, bisphenol A (BPA) is one of the most important bulk chem-
icals in the world. The global volume of BPA consumption for different application areas was 
estimated at 7.7 million metric tons in 2015 and is expected to reach 10.6 million metric tons in 
2022 at a compound annual growth rate (CAGR) of 4.8 % between 2016 and 2022 [1]. However, 
despite the large number of studies on the toxicity and hormonal activity of BPA, there are still 
open questions and thus considerable media attention regarding BPA toxicity.  
1. BISPHENOL A - STRUCTURE AND USE 
Bisphenol A is an organic chemical synthesized by condensation of 2 mol phenol with one mol 
acetone in the presence of an acidic catalyst (Figure 1). The chemical formula is C15H16O2 (Figure 
2), with a molecular mass of 228.29 g/mol .  
 
                     phenol        acetone phenol bisphenol A 




BPA is a fairly water-soluble compound [2] (300 mg/L at room temperature) and dissociates in an 
alkaline environment (pKa of BPA: 9.9–11.3).  
   
 
 















Polycarbonate plastic is used to make a variety of common consumer products, including baby 
bottles, sports equipment and medical devices, thermal [3] or recycled paper. Polycarbonate plas-
tics are typically clear and rigid. Due to these properties, there are numerous applications for pol-
ycarbonate, such as CDs, food packaging materials, such as plastic containers for food and drinks, 
baby bottles, lining materials for dental sealants and orthodontic products, eyeglasses, sports safety 
equipment, medical equipment, visors for helmets, and microfibers [4, 5]. Epoxy resins are used 
as coatings for the inside of almost all food and beverage containers [6, 7] to prevent the contents 
from a direct contact and a possible reacting with the metal.  
 
 






1.1. RELEASE AND HEALTH IMPLICATIONS 
Bisphenol A can be easily released from its corresponding polymers by the following mechanism. 
The ester bond connecting the BPA molecules in polycarbonates or epoxy resins is hydrolyzed 
during heating or in acidic or alkaline medium. As a result, free BPA is released and can migrate 
into food, beverages and finally into the environment and may be taken up by the oral route. More-
over, migration is enhanced by repeated washing with detergents, rubbing and sterilization.  
Bisphenol A can be easily absorbed by the oral route. It enters the animal and human body by 
ingesting foods and drinks that are contaminated with bisphenol A from polycarbonate bottles 
and cans coated with epoxy resins. 
The human endocrine system controls many biological processes and is important for regulating 
homeostasis in the body. BPA has the capacity to mimic the effects of the female sex hormone 
estrogen and thus antagonize 17β-estradiol (E2), the most active estrogen (Figure 4). There is 
substantial evidence indicating that BPA has structural features that confer the ability to bind to 
both nuclear estrogen receptors (ERs), ERα and Erβ, which can trigger various physiological ef-
fects [8, 9]. It was found that BPA contributes to the risk of cancer [10], the development of mental 
problems, obesity, metabolic syndrome, and BPA possibly also contributes to infertility and sub-
fertility. The mechanisms at the root of these multiple effects are numerous and involve BPA bind-
ing to membrane and nuclear estrogen receptors, interference with other nuclear and nonnuclear 
receptors [11, 12], and alterations in the synthesis or in the metabolism of hormones, as well as 
epigenetic deregulation.  
 
Bisphenol A 17β-estradiol 






1.2. BISPHENOL A (BPA) REGULATIONS 
BPA has become subject to product regulations because of growing concerns of toxicological sig-
nificance from its potential to disrupt the hormone balance by mimicking estrogens. Canada was 
the first country to declare BPA as a toxic chemical in 2008 [13, 14]. For example, by 2020, the 
regulation body REACH mandates that thermal paper must not contain a BPA concentration equal 
to or greater than 0.02 % by weight.  
A specific migration limit for BPA in food or food simulant has been set to 0.05 mg/kg of food 
(European Commission, Commission Regulation (EU) 2018/832 of 12 February 2018) [15]. Reg-
ulation 2018/213 [2] banned the use of BPA in the European Union for feeding bottles, plastic 
cups and packaging containing food intended to be used by infants and children younger than 3 
years old. 
In January 2015, the European Food Safety Authority [2] issued a new value of tolerable daily 
intake (TDI) of 4 μg/kg of body weight per day of BPA. Previously, the amount of BPA exposure 
that the EFSA considered “safe” was a TDI of 50 μg/kg of bodyweight (bw)/day (equivalent to 
0.05 mg/kg of bw/day) [2]. The EFSA estimates an exposure of approximately 1.5 μg/(kg and day) 
in adults and 0.2–13 μg/(kg and day) in infants and children just from food sources alone. The 
Food and Agricultural Organization within the World Health Organization (FAO/WHO) issued a 
tolerable daily intake (TDI) of 1.5–4.2 μg BPA/kg bw/day in 2010 [16]. In 2012, the United States 
Food and Drug Administration (FDA) banned the use of BPA in baby bottles intended for children 
under 12 months [17, 18]. In July 2013, the FDA completely banned the use of BPA in coating 
compositions that are used in packaging materials for products to be used with infants. A study by 
Vandenberg et al. [19] in the United States proved that BPA was found in 93 % of the tested urine 
samples with detectable levels.  
These regulations exemplarily demonstrate that early prevention of contaminations of food and 





1.3. ANALYTICAL METHODS TO QUANTIFY BISPHENOL A 
Several analytical methods have been proposed to detect and quantify bisphenol A in plastic ma-
terials, food, and beverages. Bisphenol A analysis has frequently been performed by gas chroma-
tography, mostly after derivatization, and liquid chromatography, applying mass spectrometric or 
fluorescence detection. An overview is given in Table 1.  
 
The sample preparation constitutes the key step to determine BPA in different matrices. Although 
the conventional analytical methods are usually very sensitive and accurate, they are technically 
complex, time-consuming, require costly and sophisticated instrumentation and do not allow for 
field portability or high-throughput analysis [31]. Hence, it is necessary to develop a sensitive, 
simple, cost-efficient, specific, portable, and rapid method for monitoring bisphenol A and in par-
ticular, for high sample through-put and on-site screening analysis. 
Table 1 Analytical methods of determination for bisphenol A. 
 
Instrumental methods Substance Sensitivity Reference 
LC-MS/MS Beverages, water samples, 
plastic materials; milk samples; 
breast milk.  




Beverages: sweet corn, peas 
with carrots; 
 human breast milk 
LOD 3 pg/mL 









LOD 0.44 pmol/mL 
LOQ 1.10 pmol/mL 
LOD 0.02 μg/kg 
[27] 
[28, 29] 




2. IMMUNOCHEMICAL METHODS – STATE OF THE ART  
Immunoassays display a platform for clinical diagnostics studies, biopharmaceutical analysis, en-
vironmental monitoring, and food testing, that quantifies and identifies unknown analytes in the 
sample based on antibody-antigen interactions [32].  
Immunoassays offer several advantages, such as simplicity and specificity comparable with the 
conventional analytical methods. Immunoassays are cost-effective and more importantly, on-site 
analysis is also possible. The ease of automation, an efficient and high throughput, and the versa-
tility in the applications of immunoassays have contributed to make this method more and more 
popular in recent years. 
Antibodies are the essential reagents that play a critical role in various bioanalytical methods, such 
as immunoassays. A large part of biotechnological research deals exclusively with the production 
of antibodies [33, 34]  , not only for science research or diagnostic purposes but also for therapeutic 
purposes.  
2.1 Antibody structure and production 
Antibodies are immune system-related proteins called immunoglobulins. Antibodies are divided 
into five major classes, IgM, IgG, IgA, IgD, and IgE, based on their constant region structure and 
immune function. The most common type of antibody for immunoassays is the IgG class of im-
munoglobulins. IgG antibodies are Y-shaped proteins (Figure 5) that consist of two light polypep-
tide chains (25 kDa) that are linked together by disulfide bonds and identical heavy polypeptide 
chains (50 kDa).  
The light and heavy chains both have one variable domain (VL and VH, respectively), and addi-
tionally the light chain has a single constant domain (CL and CH, respectively), whereas the heavy 
chain contains three constant domains (CH1, CH2, CH3). The two antigen-binding fragments (Fabs) 
are responsible for binding to the target, whereas the highly conserved Fc (fragment crystallizable) 
region interacts with effector molecules. Each variable domain (VL and VH) contains three hyper-
variable loops, known as complementarity determining regions (CDRs), evenly distributed be-
tween four less variable framework (FR) regions. It is the CDRs that provide a specific antigen 
recognition site on the surface of the antibody, and the hypervariability of these regions enables 
antibodies to recognize an almost unlimited number of antigens. From an analytical point of view, 
7
the most relevant region is the paratope, also called antigen-binding site; that is the part of an 
antibody which recognizes and binds to an antigen [35]. The selectivity and sensitivity of an im-
munoassay are controlled by the nature of the antibody–antigen binding process.
Figure 5. Structure of IgG
There are two primary types of antibody [36], namely monoclonal and polyclonal, which are de-
termined by the means in which they are produced. 
2.1.1. Polyclonal antibodies
Polyclonal antibodies are produced by injecting an immunogen into an animal with different 
epitopes that characterize the particular immunogen. Relatively large animals, such as rabbits, 
goats, sheep, guinea pigs, donkeys and fowl, have all been used for the generation of polyclonal 
antisera. The chosen subject used for the immunization depends on the type and quantity of anti-
serum required, on the previous success of the particular type of animal and on the cost and welfare 
of the animal. After being injected with a specific antigen to elicit a primary immune response, the 
animal is given a secondary even tertiary immunization to produce higher titers of antibodies 
against the particular antigen. Rabbits and sheep are frequently used for the production of polyclo-
nal antiserum because they are cheap and easy to handle for immunization and bleeding purposes. 




techniques. Polyclonal IgGs can bind to different epitopes of the same antigen, may cross-react 
with structurally related molecules, and there is little consistency between batches [33]. 
2.1.2 Monoclonal antibodies 
Monoclonal antibodies are produced by the same clone of plasma B cells, and they bind to a unique 
specific epitope on the antigen. The first system for the production of monoclonal antibodies was 
reported by Köhler and Milstein in 1975 [37]. It provided an alternative method for antibody pro-
duction, resulting in the isolation of a homogenous antibody population. The chosen subject used 
for the immunization is mouse or rat, then B lymphocytes are generally isolated from an immun-
ized animal and the cells are fused with the myeloma cell to obtain an immortal population of 
hybridoma cells. The hybridoma cells are cultured in HAT ((hypoxanthine, aminopterin and thy-
midine)-supplemented media) medium in order to obtain large populations of monoclonal plasma 
B hybridoma cells. This HAT selection system was previously described by Littlefield et al. [38, 
39]. Monoclonal antibody (IgG) can be harvested from culture vessels. Monoclonal IgG are ex-
pensive to produce, require skills to handle cell culture technology for the production and are time-
consuming. Yet, assays based on monoclonal IgG may exert less cross-reactivity and it is straight-
forward to produce them reproducibly. 
Small molecules, such as bisphenol A, are classified as haptens. A “hapten” is a low-molecular 
mass molecule that reacts with a specific antibody but cannot elicit an immune response unless 
conjugated to a large molecule, for example a protein. Designed haptens usually consist of a mo-
lecular “spacer” arm (linker) for their covalent attachment to carrier proteins. It has been proven 
that the structure of a hapten and the length of the hapten spacer has influence on affinity and 
specificity of the antibody and the sensitivity of the resulting immunoassays [40].  
Low molecular weight and one antigenic determinant of hapten impede the simultaneous binding 
of two or more antibodies [41, 42]. Therefore, competitive immunoassays are the main format for 




2.2. Enzyme-linked immunosorbent assay (ELISA) 
Immunoassays can be divided into two groups: homogeneous and heterogeneous. A heterogeneous 
immunoassay, such as in the ELISA methods, are based on enzyme-catalyzed (horseradish perox-
idase (HRP)) reaction resulting in the generation of an optical signal. By using chromogens, such 
as tetramethylbenzidine (TMB), the terminal measurement of absorbances by a simple UV-vis 
photometer is enabled [43].   
2.2.1. Indirect competitive ELISA  
In the indirect competitive ELISA, a hapten-protein conjugate is first immobilized on the surface 
of a flat-bottom well of a 96-well microtiter plate (MTP) possessing high protein-binding capacity 
(Figure 6 A).  
Unoccupied binding sites are blocked with casein to prevent non-specific binding of the antibody. 
In the next step, analyte (BPA) is added. Then, analyte and hapten-protein conjugate compete for 
the binding sites of the primary antibody specific to BPA (anti-BPA IgG). When the analyte binds 
to the antibody, it remains in the solution and is removed with the next washing step. If the conju-
gate binds to the primary antibody, the antibody is fixed to the surface of the microtiter plate. For 
detection of the primary antibody, a secondary antibody (enzyme-labeled IgG specific to the pri-
mary antibody) is added. The quantification is carried out here again by measuring the absorbance. 
The amount of surface-bound antibody is indirectly proportional to the analyte concentration in 
the sample.  
2.2.2. Sandwich ELISA 
The sandwich ELISA measures the amount of analyte, which is bound between two antibodies. 
As in the assay two antibodies are required, the sandwich ELISA is restricted, because the analyte 
must contain at least two epitopes [43] and two different antibodies are needed.  
To perform this assay, a “capture” antibody is immobilized on the surface of the well of an (MTP). 
Unoccupied binding sites are blocked with casein to prevent non-specific binding of the analyte. 
The analyte is then added and bound or captured by the “capture” antibody. Unbound analyte is 
removed with the next washing step and an enzyme-labeled “detection” antibody is added, which 
recognizes a distinctly different epitope on the analyte, thus completing the sandwich. The assay 
is then quantified by measuring the amount of detector antibody bound (an enzyme-labeled 
10
antibody) using a colorimetric substrate (TMB). In this case, IgG can be an analyte. An example 
of the assay is demonstrated in Figure 6 B.
Figure 6 A. Schematic illustration of a competitive indirect ELISA for determination of BPA. B.
Schematic illustration of a sandwich ELISA
2.3. Fluorescence polarization immunoassay (FPIA)
A prominent example of a competitive homogeneous immunoassay, the Fluorescence Polarization 
Immunoassay (FPIA), was first described by Dandliker and Feigen (1961) [44]. In contrast to 
ELISA, for the quantification of the antibody-antigen reaction the immobilization of reagents is 
not required, and the sample constituents are in contact with the antibody and tracer for a prolonged 
time. It can be performed in a single step and there is no need for any washing steps which makes 
the entire procedure easier and faster since the procedure is just mixing the reagents. So, FPIA is 
sometimes classified as a mix-and-read assay [45, 46]. Lastly, sample constituents that might in-
terfere with the fluorescence measurement, either via intrinsic fluorescence or by quenching, have 
to be evaluated for their effect on assay performance.
The signal originates from observing the fluorescence emission of an analyte-fluorophore conju-
gate (the tracer) [47]. It is added to the sample and the mixture excited by plane-polarized light, 
produced via a polarizer between lamp and sample cuvette. The emitted fluorescence radiation is 
recorded via a photomultiplier in front of which another polarizer is positioned. An intensity value 
of the incident light is recorded (“parallel”, I║) and then a second value after rotating the second 
polarizer by 90° (“perpendicular”, I ). Some instruments possess a second detector in 90° position 




recordings (in the case of equal sensitivity in both directions) is called fluorescence polarization 
FP (reported in millipolarization units, mP) [48]. The following formula is used to calculate the 





The phenomenon of FP is also known as anisotropy r. It only differs in the way of calculation; for 
anisotropy, the perpendicular intensity in the denominator is counted twice (I║ + 2I ).  
This denominator term describes also the total fluorescence intensity of polarized light. The G 
factor is a measure of the instrument-specific geometry, which dependents on the applied wave-
length. The G factor is determined by measuring the intensities in parallel and perpendicular po-
larizer settings, while the polarizer for the exciting light is rotated by 90° compared to normal 
polarization measurement. In other words, the ratio of the perpendicularly and parallelly measured 
intensities is the G factor [48]. 
Then, antibody is added in solution. Two extreme examples may illustrate the processes that take 
place:  
If (a) no (or a small amount of) analyte is present in the solution, the larger fraction of the tracer 
binds to the antibody. As a result, its orientation in space, which before was in steady change due 
to Brownian motion, rotation and diffusion, is rather conserved: the registered intensity values of 
both detectors gradually decline while differing strongly from each other and after reading at a 
fixed time, a large polarization FP is registered. 
If (b) there is a high analyte concentration in the mixture, mostly analyte molecules bind to the 
antibody added, the tracer remains largely “free” (and, therefore, subject to Brownian motion, fast 
rotation, and diffusion) so that in consequence the incident polarized light is transformed to depo-
larized fluorescence emission in all directions: little light hits the detector and I⊥ is similar to I║, 
resulting in a small difference, i.e., a small value for the polarization FP. Plotting FP against the 
analyte concentration on a logarithmic scale results in a sigmoidal curve as with all immunoassays. 
As fluorophore, in the large majority of applications, fluorescein is used, and the instruments are 
adapted to its peak excitation at 494 nm and peak emission at 521 nm for measurement.[43, 49, 
50]. According to the assay steps, FPIA is a technique where kinetics play an important role. 
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Therefore, the length of all incubation steps (i.e., the time after addition of the tracer and before 
addition of the antibody, and the time after which the read-out is recorded) has to be optimized in 
order to obtain a sensitive assay and controlled in order to obtain good reproducibility. The sche-
matic principle of FPIA is shown in Figure 7. Plotting mP against the analyte concentration on a 
logarithmic scale results in a sigmoidal curve as with all immunoassays [46]. 
Figure 7. Schematic principle of FPIA for determination of BPA
2.4. Lateral flow immunoassay (LFIA)
The lateral flow immunoassay (LFIA), also known as dipstick assay or immunochromatographic 
assay (ICA), is a type of a membrane strip for detecting the presence of a target analyte in the 
sample. LFIAs have first been reported in the early 1980s; and in 1984, the first commercial lateral 
flow strip product was launched as a urine-based pregnancy test [51]. Due to low-cost materials in 
the manufacturing process, a relatively short assay development time, affordability, sensitivity, 
specificity, user-friendliness, speed, robustness, and equipment-free use (it has ability to be oper-
ated by people without professional training) the LFIA has become a widely used format. Lateral 
flow devices meet the World Health Organization’s (WHO) criteria for point-of-care diagnostics 
and technology has been employed to develop a wide and growing range of tests for clinical, vet-
erinary, agricultural, food industry and environmental applications [52, 53]. The qualitative 
method provides a positive response when the target analyte content is higher than a set threshold
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and the results can be assessed with strip readers (color density scanners, fluorescence scanners),
including smartphone-based strip readers [54–57]. 
According to Markets & Markets, (https://www.marketsandmarkets.com/), the lateral flow assay 
market was valued about 5 billion Euro in 2017 and is expected to reach 10 billion Euro by 2026.
Nowadays, several different types of the lateral flow devices are available, such as for infectious
diseases testing, mosquito-borne disease testing, influenza testing, sexually transmitted infection 
testing, HIV testing, HPV testing, chlamydia testing, gonorrhoea testing, syphilis testing, hepatitis 
testing, tuberculosis testing, and SARS-CoV-2 testing. The lateral flow assay market comprises 
hospitals and clinics, diagnostic laboratories, personal home care, pharmaceutical and biotechnol-
ogy companies and private end users.
A database search for patent applications using Google Patent Search (https://patents.google.com/)
with the search terms “lateral flow”, “lateral flow device” and “immunochromatography” for the 
years 2000 to 2019 yielded 5000 hits. According to the Google data base the annual numbers of 
patent applications follows a growing trend. 
2.4.1. Elements of Lateral Flow Immunoassays
A Lateral flow immunoassay is based on different components, each serving one or more purposes. 
The LFIA strip includes a sample pad, a conjugate pad, a wicking or absorbent pad and a nitrocel-
lulose membrane, which are all applied to a self-adhesive plastic backing card [56, 58]. Figure 8
shows the typical configuration of an LFIA strip. 





The sample pad is commonly manufactured of rayon, glass fiber or cellulose (Fig. 8) (Table 3). 
The sample pad is the first material on the strip which has contact with the sample liquid. The main 
function of the membrane is to absorb the sample fluids and treat it such that it is compatible with 
the assay and that it will release the analyte with high efficiency to the analytical membrane via 
the conjugate release pad. Sample treatments include the filtering out of particulates, changing the 
pH of the sample, actively binding sample components that can interfere with the assay, and dis-
rupting matrix components, such as mucins, in order to release the analyte to the assay [56, 59]. 
Conjugate pad  
The conjugate pad is commonly manufactured of glass fiber (Fig. 8) (Table 3). For the best result, 
the material must be hydrophilic and allow a rapid flow rate. The role of the conjugate pad is to 
accept the antibody−gold nanoparticles (IgG−GNPs) or antibody−latex microparticles 
(IgG−LMPs) conjugate, hold it stable and release it when the liquid flows across it. To ensure 
optimal release and stability it is often necessary to pre-treat the conjugate pad [56, 60, 61].  
Absorbent pad 
The absorbent pad is usually manufactured of high-density cellulose (Fig. 8) (Table 3). The role 
of the pad is to wick the fluid through the membrane and to collect the processed liquid. The 
absorbent pad allows to increase the sample volumes, which results in increased test sensitivity. 
Moreover, proper choice of the absorbent pad could increase the speed of signal development or 
by limiting the liquid capacity it can be used to stop the liquid flow at a desired time. The choice 
of wicking material is generally dictated by absorptive capacity, cost, and capillarity [55, 56].  
Nitrocellulose membrane  
The nitrocellulose membrane is one of the most important materials used in lateral flow immuno-
assay devices (Fig. 8). The main function of the nitrocellulose membrane is to bind proteins at the 
test and control areas and to maintain their stability and activity. Proteins bind to nitrocellulose 
through a combination of electrostatic interactions (see structure in Fig. 9), especially through the 
interaction of the strong dipole of the nitrate ester with the strong dipole of the peptide bonds of 





Figure 9. Chemical composition of a nitrocellulose polymer subunit 
The nitrocellulose membranes are available in various pore sizes, porosities, and thicknesses (Ta-
ble 4) [63].  
Many factors affect the binding process, and these must be considered when developing assays 
and processing nitrocellulose membranes. Some of these factors are listed below [56, 63]: 
(i) Membrane’s protein binding capacity 
It is determined by the amount of polymer surface area available for immobilization. The avail-
able surface area is determined by capillary flow rate, pore size, and thickness. 
The capillary flow time is directly related to pore size. A larger pore size correlates with a faster 
flow and a smaller pore size correlates with slower flow across the membrane (Table 4). The 
membrane with smaller pore size (long capillary flow time) will increase the assay time. Slow 
speed increases the incubation time between the particles, the analyte, and the test line, which 
can increase the sensitivity. It is important to screen membranes for each assay from a variety of 
manufactures.   
(ii) Reagent choices 
The loading capacity of a protein (IgG, OVA, BSA, casein, gelatin etc.) on a given surface area 
depends on the protein’s compactness in structure and its Stokes radius (effective diameter). For 
IgG, the approximate loading capacity is 1 μg/cm2. Multiplying the loading capacity of IgG (1 
μg/cm2) by the surface area ratio of the membrane (50 – 200) produces an approximate IgG 
binding capacity of 50 – 200 μg/cm2. In a typical test strip, the test line is 1 mm wide. If the strip 
is 1 cm wide, the amount of capture reagent that can be bound is 5 – 20 μg (0.1 cm width x 1 cm 





(iii)  Environment 
Humidity and temperature should be optimized for increase the binding capacity of the mem-
brane. Preliminary to striping/spotting, the nitrocellulose membrane needs to be equilibrated to 
a controlled humidity environment of ~50 % relative humidity (RH).  
Nitrocellulose membranes that are too dry may result in spotty, non-uniform lines, whereas ni-
trocellulose that is too damp will result in a widened test line that may decrease the signal inten-
sity. Usually, it is recommended that after receiving new membranes, to expose the membrane 
to the “wet room” environment overnight or for a period of 8 to 12 hours prior to striping.  
(iv) Dispensing methods 
For dispensing the proteins onto the nitrocellulose membrane either contact or non-contact dis-
pensing systems can be used. The non-contact systems are preferable, they provide precise 
amounts of reagent to be as quantitative as possible. Important parameters for the spotting process 
include the reagent concentration and dispensing rate.  
(v) Blocking reagents  
The purpose of blocking a nitrocellulose membrane is to prevent the binding of proteins and label 
conjugate to the membrane at areas other than the test and control lines. It also serves other 
functions, including maintenance of hydration of membranes, modification of wicking rates, and 
stabilization of test and control line proteins. 
(vi)  Drying time and methods 
These can affect the arrangement and activity of proteins on the membrane. After the strip-
ing/spotting, the membrane is exposed to an elevated temperature for some time (e.g., to 37 °C 
for one hour) to remove the excess water from the deposited striping solution. The membrane is 
then allowed to dry further by being kept in a controlled humidity environment of < 30 % RH to 





2.4.2. Antibody−particle conjugates 
The main component of LFIA is the detector particles that are decorated with antibodies [64]. A 
common type of detector particles used in LFIA are gold nanoparticles and latex microparticles 
for visualization purposes, which appear as a colored line when bound at a specific location on the 
membrane [56, 65]. Because the optical properties of gold nanoparticles are dependent on size and 
shape, the sensitivity of LFIA is limited by the intensity of the signal from the small (typically 40 
nm in diameter) reporter particles [66, 67]. If the clinically relevant range of the analyte cannot be 
reached, the lateral flow strip will not have a commercial market.  
The particle size is the important factor that influences the wicking time. Capillary rise of larger 
gold nanoparticles (≈ 40 nm) through lateral flow membranes was slower than for smaller ones (≈ 
20 nm) [16]. The latex microparticles size was 300 nm, and their mobility was sufficiently de-
creased. However, several studies showed that a decreased mobility of larger particles resulted in 
a better assay sensitivity [68]. Good mobility of the latex microparticles also depended on the 
wicking time of the membrane and its pore size [69, 70]. Antibodies are composed of amino acids, 
some with reactive side chains which can be utilized for covalent coupling with particles contain-
ing superficial functional groups that have been produced previously on the particles [71]. An 
alternative simple method for conjugation of proteins with particles is via passive absorption [72] 
which is based on three separate but dependent phenomena:  
1) ionic attraction between the abundant positively charged sites on the antibody and the negatively 
charged gold nanoparticles 
2) hydrophobic interaction between the antibody and the gold surface 
3) dative binding between the gold conducting electrons and amino acid sulfur atoms of the anti-
body 
According to Nardo et al. [73], covalent coupling of antibodies to gold nanoparticles has more 
benefits, such as low risk of aggregation during the coupling process, no dependency of the cou-
pling efficiency on coupling conditions, that generally less antibody is required than for passive 
absorption, and the higher stability of the conjugate. However, passive absorption is a traditional 
method of conjugation, little chemistry is involved in contrast to covalent coupling that requires 
an additional activation step for the carboxyl group on the surface of the particles with EDC and 
NHS chemistry). Clearly, passive adsorption is performed at less cost [74]. Moreover, conjugating 
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proteins, for example, with gold nanoparticles can lead to diverse affinities for their antigens de-
pending on how the antibodies are immobilized. 
2.4.3. Variants of Lateral flow immunoassay format
2.4.3.1. Sandwich format
The sandwich format of LFIA is used for high molecular weight analytes with multiple antigenic 
sites [56, 75]. The best-known example of this format is the pregnancy test. It works by detecting 
human chorionic gonadotropin (hCG). To perform this assay, two analyte-specific antibodies are 
used separately as “capture” and “detecting” reagents [55, 56, 76, 77]. If there is target present in 
the sample, it will be sandwiched between the “detector” antibody−gold nanoparticle conjugate 
and the ”capture” antibody on the test line, yielding a positive signal. A positive test is represented 
by the presence of a colored test (T-line) and control line (C-line) (Figure 10 B). The response is 
directly proportional to the amount of analyte in the sample. A negative test is represented by the 
absence of a T-line (Figure 10 A). The control line zone will always bind the surplus antibody-
nanoparticle conjugate, yielding a strong control line signal that demonstrates that the assay is 
functioning correctly.
Figure 10. Schematic illustration of a sandwich LFIA. A. Negative result. B. Positive result 
2.4.3.2.   Competitive format
Competitive LFIA format used for low molecular weight analytes that have only one epitope, such 
as for the determination of bisphenol A [78, 79]. To perform this assay, an analyte–protein conju-
gate is applied at the T-line, and nanoparticle-conjugated analyte-specific antibody is applied at 
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the conjugate pad. In order to verify that the device does, indeed, function, a control line is often 
added to provide a control signal. Thus, when the solution does not contain any target analytes in 
the sample, the antibody gold nanoparticle conjugate will bind to the T-line and the C-line, yielding 
a strong signal intensity. If the analyte is present in the sample, the antibody−nanoparticle conju-
gate will bind the analyte in solution and will not be able to bind to the immobilized analyte-protein 
conjugate, thus diminishing the intensity of the test line signal (Figure 11).
Figure 11. Schematic illustration of competitive LFIA. A. Positive result is seen when the ana-
lyte becomes bound to the analyte-specific antibody and therefore cannot bind to the analyte-pro-




2.5. ANALYTICAL PERFORMANCE DESCRIPTION OF IMMUNOASSAYS 
Four-parameter sigmoidal fitting is the most commonly used with immunoassays. The calibration 
curves are fitted to the mean absorbance values (ELISA), intensities (LFIA) or FP values (FPIA) 




+  (1) 
 
Where S is the mean value of the signal, and c is the analyte concentration. The variables A to D 
were assigned to specific features of the curve: A (upper asymptote), B (slope at the inflection 
point), D (lower asymptote) and Co (the inflection point, midpoint) (Figure 12) [81]. The Co pa-
rameter is often equal to the 50 % inhibitory concentration (IC50) of the calibration curve and 
indicates the concentration of analyte which induces a response halfway between the upper as-
ymptote and lower asymptote after a specified exposure time. The concentration of 50 % inhibition 
is a measure of the sensitivity of immunoassays. The lower the IC50 the more sensitive is the im-
munoassay. Due to Weller et al., the computing of affinity constants can be accomplished when 
extrapolating the found midpoint (IC50) of both enzyme conjugate and antibody approaching zero 
in a series of dilutions [82, 83]. The correlation coefficient (R2) is one of the primary criteria for 
goodness of fit and must be at least 0.90 [84].  
















Figure 12. Example of calibration curve (gray solid line) used to correlate signal with analyte 
concentration 
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The measurement range was assessed applying the concept of the precision profile (a response 
error relationship) according to Ekins [85] by calculating the relative error for each calibrator con-




+ 2 +  
(2) 
A function, = ( ) + + , developed before [86], allows to fit a continuous line to the 
data points of the precision profile, with a, b, c, d, and e being variables, x being the concentration 
of the analyte. The precision profile of immunoassays shows a typical U shape (Figure 13). A 
relative error of the determined concentration of 30 % was considered allowable to mark the limit 
of detection (LOD).  
The determination of the limit of detection (LOD) can be made in several ways and has therefore 
been subject for discussion [87]. For a linear calibration curve, it is assumed that the instrument 
response y is linearly related to the standard concentration x for a limited range of concentration 
= + . The model is used to compute the sensitivity b and the limit of detection (LOD) [88] 
(Equation 3). 
= ,  ×  (3) 
where σ is the standard deviation of the response and m is the slope of the calibration curve. 
In the immunoassays the limit of analyte detection (LOD) is, for simplicity, often set to 20 % of 
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Figure 13. Example of calibration curve of and precision profile (dotted line shows moving av-
erage of three adjacent points) using three replicates per calibrator










2.6. SELECTIVITY OF ANTIBODY  
In addition to the actual target analyte, structurally similar compounds are also detected in an im-
munoassay. The reason for this is that these compounds also fit sterically and electronically into 
the binding site of the antibodies. Therefore, they can cross-react with similar epitopes of com-
pounds structurally related to the target analyte, but usually with less affinity. In order to estimate 
how large the influence of cross-reactions on an assay is, different substances structurally related 
to the analyte itself are tested. Antibodies with a broad cross-reactivity (CR, in %) pattern can be 
used to simultaneously detect a group of structurally related compounds and for the development 
of broad-specificity screening immunoassays. This effect can often be observed in polyclonal an-
tibodies, as different antibody fractions are present in the serum [90]. But for the accurate and 
precise determination of one analyte, only low or ideally no cross-reactivities are desired. 
Immunoassay selectivity was tested by assaying several compounds structurally related to bi-
sphenol A. The specificity of the monoclonal antibody and selectivity of the assay was evaluated 
[91] by determining their IC50 values (midpoints, parameter C in the 4-parametric sigmoidal fitting 
curve ~half maximum inhibitory concentration) and calculating their cross-reactivity (CR, in %) 
as follows: 
% =  
( )
(  )
 ×  100 % 
 
When an antibody binds to unintended proteins, to particles or to sensor surfaces by simple ad-
sorption, hydrophobic, and other types of interactions, we speak of “non-specific binding” (NSB). 
Although the causes of non-specific background immunostaining may differ, they all equally com-
plicate the use of immunoassays. However, this is not an actual affine detection and the problem 





2.7. IMMUNOCHEMICAL METHODS FOR THE DETERMINATION OF BISPHENOL A 
Immunoassays have been studied and used for the detection of BPA, and many research reports 
deal with antibody production and the development of heterogeneous immunoassay methods, such 
as the established ELISA and FLISA methods, which both need immobilization of one binding 
partner and several washing steps. Due to these time-consuming steps, they are not suitable for the 
demand of a fast, efficient, and high-throughput screening method. A homogeneous immunoassay, 
such as the Fluorescence polarization immunoassay (FPIA), does not require the immobilization 
of reagents, can be operated in a single phase, and does not need further washing steps which 
makes the entire procedure faster (Table 2) [106, 107].  
 
The use of membrane-based immunoassay tests for rapid on-site screening provides a simple and 
low-cost alternative to expensive, laborious and time-consuming instrumental methods and also to 
more sophisticated immunoassay formats [108–110]. The lateral-flow technique or immunochro-
matography is the most advanced and user-friendly format in terms of simplification and rapid on-
site testing. The one-step lateral-flow method with the use of gold nanoparticles-labeled antibod-
ies, based on the transportation of a reactant to its binding partner immobilized on the membrane 
surface, offers several advantages, including short assay time, visual interpretation of results, long-
term stability and cost-effectiveness. Few studies were performed on the development of gold-
based technique lateral flow immunoassays for BPA (Table 2), leaving room for optimization and 
improvement. 
Table 2 Immunochemical methods for the determination of bisphenol A. 


















FPIA Water samples 
Environmental water 
LOD 5.60 ng/mL  
 
[99, 100] 




Other modifications of LFIA 
Baby bottles 
 
Water samples  
LOD 100 ng/mL 
LOD 10 ng/mL 
LOD 4 μg/L 








II. OBJECTIVES OF THE STUDY  
The work presented in this thesis deals with the development of low-cost, flexible, rapid, and easy-
to-use immunoassay techniques for determination of the endocrine disruptor bisphenol A.   
To achieve the objectives of this study, the following work packages have been formulated: 
(a) to synthesize the required hapten-protein conjugate and to develop a sensitive competitive 
lateral flow immunoassay (LFIA) device with colorimetric detection from these reagents, 
which can be evaluated visually and using program for a data visualization and image anal-
ysis or using a portable scanner. 
(b) to examine the use of gold nanoparticles and latex microparticles as markers (as signal 
reporter) in LFIA, and to evaluate the potential of improving assay sensitivity and the ca-
pability to produce quantitative results. 
(c) to examine different types of nitrocellulose membranes and glass fibers, which can be 
translated into an increase in sensitivity and an improved detection limit for this LFIA de-
vice. The influence of some critical parameters on the sensitivity of the device should also 
be thoroughly assessed.  
(d) to synthesize new tracer molecules, linking the fluorescein fluorophore with and without a 
spacer to the bisphenol A moiety, and assess for performance in the fluorescence polariza-





III. MATERIALS AND METHODS  
3.1. Materials and Equipment  
Transparent microtitre plates with 96 flat-bottom wells possessing high protein binding capacity 
(MaxiSorpTM) were purchased from Nunc (Thermo Scientific). UV-transparent 96 wells micro-
titre plates, UV-Star™, were purchased from Greiner bio-one (Frickenhausen, Germany). TLC 
plates used were silica gel 60 with/without concentration zone, with/without fluorescence indicator 
from Merck KGaA (Darmstadt, Germany). Filters syringes with a Teflon membrane with a pore 
size of 0.45 μm and 17 mm in diameter from Merck KGaA (Darmstadt, Germany). PD-10 columns 
containing Sephadex G-25 were obtained from GE Healthcare (Munich, Germany). The LFIA test 





Table 3 Absorbent pad, conjugate pad, sample pad used within this thesis (were purchased from 
Merck. 
Merck Millipore MDI Membrane 
Technologies 
 
 Product name Material Product name Material 























































































































































   
   
   
   























   
   
   
   

















   
   
   
   
   
   


















   
   


















    
   
   
   
   











































































































































































































































































































































































































































































































































































































The anti-bisphenol A mouse monoclonal antibody was provided by the lab of Professor Chuanlai 
Xu (School of Food Science & Technology, State Key Lab of Food Science and Technology 
Jiangnan University, Wuxi, Jiangsu, China) buffered (7 mg/ml in 0,01 M PBS, pH 7.4, 1 % BSA, 
1 % glycerol azide 0.02 %) [79, 100, 111]. Polyclonal goat anti-mouse HRP labeled antibody 
(clone A4416) (whole molecule, with 0.5–3 mg/ml in 0,01 M PBS, pH 7.4, 1 % BSA, azide 0.02 
%) provided by Merck Millipore, (Darmstadt, Germany). HRP-conjugated sheep anti-mouse-IgG 
(R1256HRP) and sheep anti-mouse IgG (R1256P) provided by Acris Antibody GmbH (Herford, 
Germany). 
All the reagents for buffer were purchased from Merck KGaA (Darmstadt, Germany). All buff-
ers were prepared in Milli-Q water unless other solvent is mentioned.  







10 mM sodium dihydrogen phosphate 
70 mM disodium hydrogen phosphate 






40 mM tetramethylbenzidine 
8 mM tetrabutylammonium borohydride in 
 N, N-dimethylacetamide 
 
Carbonate buffer 15 mM sodium carbonate 
35 mM sodium bicarbonate 
9.6 
Tris buffer 10 mM tris-(hydroxylmethyl)-aminomethan 
150 mM sodium chloride 
8.5 




Borate Buffer 50 mM sodium tetraborate decahydrate 
0.01 % sodium azide 
8.5 
MES buffer 0.5 M 2-(N-morpholino)ethanesulfonic acid 4.0 
Citrate Buffer 220 mM trisodium citrate 4.0 
 
N-Hydroxysuccinimide (NHS, Sulfo-NHS), N,N′-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide * HCl (EDC), chlorotrimethylsilane (TMS-Cl), abs. N,N-di-
methylformamide (DMF), ethyl acetate, chloroform, triethylamine, 6-aminohexanoic acid (Ahx), 
bovine serum albumin (BSA), D-(+)-trehalose dihydrate, sucrose, bisphenol A (BPA), bisphenol 
A-d16 (BPA-d16), bisphenol valeric acid (BVA), bisphenol B (BPB), bisphenol E (BPE), bi-
sphenol F (BPF), bisphenol S (BPS), 4-cumylphenol (4-CP), 4-octylphenol (OCP), and                   




4'-(Aminomethyl)fluorescein hydrochloride (AMF) was from Invitrogen (Carlsbad, CA, USA), 
methanol (MeOH) from J.T. Baker (Griesheim, Germany), ethanol from ChemSolute (Renningen, 
Germany). Carboxy-modified dyed latex microspheres (Estapor®, product K1-030 blue) and eth-
anolamine were provided by Merck Millipore, (Darmstadt, Germany). Gold nanoparticles (40 nm) 
were provided by nanocomposix Europe (Prague, Czech Republic). 
General instrumentation: 
MALDI-TOF mass spectra were acquired using a Bruker Reflex III MALDI mass spectrometer 
from Bruker-Daltonik (Bremen, Germany) operated with a nitrogen laser and at 20 kV acceleration 
voltage. 
Spectrophotometer SpectraMax Plus384 from Molecular Devices (Ismaning, Germany) con-
trolled by SoftMax® Pro software (v 5.2, Molecular Devices) at 450 nm and referenced to 620 nm. 
Titramax 101 plate shaker (Heidolph, Schwabach, Germany). An automatic 96-channel plate 
washer (BioTek Instruments, ELx405 Select™, Bad Friedrichshall, Germany). 
Fluorescence polarization was registered on a Sentry 2000Si (Ellie LLC, Wauwatosa, WI, USA). 
The Sentry 2000Si is a multi-well fluorescence polarization instrument. Reactions are read in black 
8 or 12-well microplate strips. The instrument is equipped with a ceramic fluid metering systems 
pump, with high volume precision. 
UV-Vis-Spectrophotometer EvolutionTM 201/220 from Thermo Scientific™ (Waltham, Massa-
chusetts, U.S.). 
All proteins were deposited onto the membrane strips using a piezoelectric printer sciFLEXAR-
RAYER S3, (Scienion AG, Berlin, Germany). Lateral flow readers opTrilyzer® and Cube® by 
Chembio Diagnostics (Berlin, Germany). Software: extra quantitative analysis of lateral flow im-
munoassay images were performed by Gwyddion v2.19. software (Czech Metrology Institute, 
http://gwyddion.net), ImageJ, 30 free image processing software (ImageJ, National Institute of 
Health; Bethesda, Maryland, USA). Origin™ 8.0 Software (OriginLab, Northampton, USA) was 
used for most of the displayed graphs. ChemBioDraw Ultra (v 18.0.1) and ChemBio3D Ultra (v 
11.0.1), from CambridgeSoft (Cambridge, United Kingdom) were used for drawing the chemical 
structures, the reaction mechanisms and 3D representations. Canon EOS 750D (Canon, Japan) 
camera and smartphone camera from the iPhone Xs (California, USA) with macro (20X) and 




BPA reference concentrations of samples were determined by LC-MS/MS using an Agilent 1260 
Infinity LC system with a binary pump, degasser, autosampler, and column heater. The chromato-
graphic separation was carried out on a Kinetex XBC18, 100 Å, 2.6 μm, 150 × 3 mm analytical 
LC column with an UHPLC C18, 3 mm guard column (both Phenomenex, Aschaffenburg, Ger-
many). As mobile phases, Milli-Q water with 10 mM NH4Ac and 0.1 % (v/v) acetic acid (A) and 
MeOH with 10 mM NH4Ac and 0.1 % (v/v) AcOH (B) were used. The system was run at a flow 
rate of 350 μL min−1 and a column heater temperature of 30 °C. An elution gradient was applied, 
starting with 80 % A for the first 15 min. Within 5 min, A is decreased to 5 % (95 % B). Then, A 
is ramped up back to 80 % within 0.5 min and maintained at this level for 14.5 min to re-equilibrate 
the column. Fifteen microliters of sample were injected. Mass spectrometric detection was per-
formed on an ABSciex 6500 Triple Quad mass spectrometer. Electrospray ionization (ESI) in pos-
itive ionization mode was employed. 
Solid-phase extraction (SPE) was performed using an automatic SPE workstation, AutoTrace™, 
from Dionex (Idstein, Germany). Extracts evaporation was achieved by using a benchtop nitrogen 
stream evaporator, SLS 02 Evaporator from SLS-Labor (Bad Münstereifel, Germany). 
3.2. Methods  
3.2.1. Synthesis of the hapten-protein conjugate and tracer  
3.2.1.1. Synthesis of the hapten-protein conjugate BVA-BSA  
Bisphenol A is a “small molecule” with a molecular weight of 228.29 g/mol. To increase its im-
munogenicity, BPA was linked to bovine serum albumin (BSA). Since BPA does not have reactive 
functional groups, such as carboxylic or amino groups, a commercially available reagent, 4,4-
bis(4-hydroxyphenyl) valeric acid (BVA), which is a structural analogue of BPA (Figure 14), was 
used as a mimotope. They have the same antigenic determinant which, coupled to a protein, can 
mimic the epitope that binds to certain anti-BPA antibodies. BVA contains a carboxyl group which 
was chosen for coupling it to amino groups on proteins, e.g., BSA [112].  
Conjugation of BVA to BSA was carried out by a modified method of Montoya’s group [95, 96], 
with minor modification. The coupling reactions were performed at pH 6 according to the follow-
ing procedure. NHS (2.6 mg in 200 μL DMSO) was mixed with EDC (4.3 μg in 200 μL DMSO) 
and BVA (5.2 μg in 200 μL DMSO). The mixture was incubated with continuous stirring for 2 h 
at room temperature. 22 mg of BSA were dissolved in 2 mL PBS pH 6. The activated BVA was 




by size exclusion chromatography on Sephadex™ G-25 in a PD-10 desalting column (Healthcare 
Bio-Sciences, Freiburg), PBS/water (1: 10; v:v) being the eluent, collecting 96 fractions into a non-
binding well plate. The efficiency of the conjugation reaction was verified by MALDI-ToF-MS 
(Fig. S 1). 
 
 
Figure 14. Reaction scheme for the synthesis of BVA-BSA  
3.2.1.2. Synthesis of the hapten-protein conjugate BVA-Ahx-BSA  
The chemical structure of the conjugated hapten will greatly determine the binding to the antibody, 
In 1969, Nobel Prize laureate Karl Landsteiner demonstrated specificity of antibodies is mainly 
directed to the distal moieties of the hapten [113]. According to Schmidt et al. [114], a linear six 
carbon aliphatic chain is considered to be the optimal spacer for enabling optimal binding. For all 
those reasons, the synthesis of functionalized derivatives of the target compound is a key to in-
crease the sensitivity of the assay. For this purpose, aminohexanoic acid (Ahx) was coupled with 
4,4-bis(4-hydroxyphenyl) valeric acid (BVA). Briefly, BVA (26.3 mg) and NHS (12.9 mg) were 
mixed with EDC (22.3 mg) in 3 mL DMSO dissolved and stirred in an amber glass vial and the 
mixture was incubated with continuous stirring for 2 h at room temperature under argon. Ahx (9.8 
mg) was dissolved in 1.5 mL DMSO and was mixed with 1.5 mL PBS (pH 6). 2.5 mL of the 







Figure 15. Reaction scheme for the synthesis of BVA-Ahx 
BVA-Ahx (Figure 15) is not indefinitely stable and is probably (partially) decomposed during the 
long period of preparative HPLC (Figure S 3). So, the freshly prepared solution of BVA-Ahx was 
added to the appropriate protein solution and reacted at room temperature for 4 h with stirring. 
22 mg of BSA were dissolved in 2 mL PBS pH 6. The activated BVA-Ahx were added dropwise 
to the protein solution. After 4 h reaction time, the protein conjugate was purified SEC on a PD- 
10 column and reaching a final protein concentration of BVA-BSA of 2.1 mg/mL and for BVA-
Ahx-BSA (Figure 16) of 2.48 mg/mL, determined by Bradford assay [115]. The efficiency of the 
conjugation reaction was verified by MALDI-ToF-MS (Figure S 2). 
 
 




The Bradford assay was used to determine the hapten-protein conjugate concentration. The Brad-
ford method is a dye-based assay and is based on the ability of Coomassie blue to bind to proteins 
causing the dye color to shift from red to blue. Use of Coomassie G-250 dye as a colorimetric 
reagent for the detection and quantification of total protein was first described by Dr. Marion Brad-
ford in 1976. The quantification is carried out by plotting a calibration curve (Figure S 8) of the 
respective protein and spectroscopic measurement (595 nm) [115]. It was founded that the con-
centration of BVA-BSA was 2.7 mg/mL, and that of BVA-Ahx-BSA was 2.8 mg/mL. 
3.2.1.3. Synthesis of fluorescein-labeled tracers (BVA-AMF and BVA-Ahx-AMF) 
The fluorescent tags were coupled to the haptens by the NHS activated ester method developed by 
Eremin and co-workers [46, 99, 116], with minor modifications. BVA and BVA-Ahx (Figure 17, 
18) NHS activated esters were previously synthesized as described in chapter 2.4.2, then added to 
1.05 mg (2.6 μmol) AMF dissolved in 10 μL of triethylamine. All products formed a yellow-
orange solution which was stirred for another 4 h before being purified by thin-layer chromatog-
raphy (TLC). 
TLC was performed on silica plates (2.5 x 7.5 cm; silica gel 60 with concentration zone, without 
fluorescence indicator, Merck). The mobile phase was CHCl3:CH3OH (4:1, v/v). For each tracer, 
the main yellow band, clearly visible under UV light (λ = 365 nm), was collected, dissolved in 
ethanol, stripped from silica via filtration through a Teflon membrane syringe filter with a pore 
size of 0.45 μm and 17 mm in diameter, and purified again by TLC (see retardation factors Rf in 
Table S 1). Ethanol as solvent was evaporated, the residue finally dissolved in 100 μL methanol, 
stored at 4 °C and later on directly used as tracer stock solution from which dilutions (Tracer 
Working Solutions) in borate buffer were prepared.  
The success of the synthesis was confirmed by LC-MS/MS (see Figures S 4, S 5, S 6, S 7). Mass 
spectra were recorded at the retention time of the largest peak in the UV trace. m/z + 1 and +Na+ 
adduct ions for each individual synthesis product could be identified. The chromatograms showed 
















Figure 18. Reaction scheme for the synthesis of BVA-Ahx-AMF  
3.2.2. Protocol of the indirect ELISA  
Optimal dilutions of BVA-BSA or BVA-Ahx-BSA and anti-BPA mouse IgG, respectively, were 
determined by checkerboard titration. Transparent high-binding microtiter plates (96 flat-bottom 
wells) were coated with the respective conjugate in PBS pH 7.5, 200 μL per well, covered with 
Parafilm®, and incubated overnight (∼18 h) on a plate shaker at 750 rpm. The plates were washed 




in PBS (1 %, w/v, 200 μL per well) for 1 h. The plates were washed again, and 100 μL of sample 
or BPA standards and diluted anti-BPA monoclonal IgG were added and incubated for 60 min. 
After a three-cycle washing step, 100 μL HRP-conjugated goat anti-mouse-IgG (R1256HRP) (Ac-
ris Antibody GmbH, Herford, Germany) diluted 1 : 20 000 in PBS buffer was added in each well 
and incubated for 1 h. After another washing step, 200 μL substrate solution (TMB) was added. 
For one plate, 22 mL citrate buffer (220 mM potassium dihydrogen citrate, 0.5 mM sorbic acid 
potassium salt, pH 4.0) with 8.5 μL H2O2 (30 %) and 550 μL TMB solution (40 mM TMB, 8 mM 
tetrabutylammonium borohydride, in N,N′-dimethylacetamide) were mixed and 200 μL was added 
to each well. Following a 20 min incubation step, the reaction was stopped by adding 100 μL 
H2SO4 (1 M). Absorbance was measured photometrically by spectrophotometer SpectraMax 
Plus384 from Molecular Devices (Ismaning, Germany) controlled by SoftMax® Pro software (v 
5.2, Molecular Devices) at 450 nm and referenced to 620 nm.  
All incubation steps were performed at room temperature on a Titramax 101 plate shaker (Hei-
dolph, Schwabach, Germany) at 750 rpm. Between individual incubation steps, the plates were 
washed with an automatic 96-channel plate washer (BioTek Instruments, ELx405 Select™, Bad 
Friedrichshall, Germany). Three-cycle washing steps were carried out with a PBS-based washing 
buffer (0.75 mM potassium dihydrogen phosphate, 6.25 mM dipotassium hydrogen phosphate, 
0.025 mM sorbic acid potassium salt, 0.05 % (v/v) Tween™ 20, pH 7.6).  
3.2.3.  Protocol of the sandwich ELISA 
Each well of transparent high-binding microtiter plates was coated with 100 μL of 2 mg/L sheep 
anti-mouse IgG in carbonate buffer and incubated for 18 h on a plate shaker. The plates were sealed 
to prevent evaporation. Following a three-cycle washing step, the remaining binding sites on the 
MTP were blocked with gelatin solution (0.1 %) in PBS buffer. After incubating for 1.30 h, the 
plates were washed again. Standards (100 μL mouse anti-BPA IgG) diluted in a range of 1 μg/mL 
– 0.05 ng/mL in TRIS buffer were incubated for 45 min. After a three-cycle washing step, 100 μL 
HRP-conjugated goat anti-mouse-IgG (R1256HRP) diluted 1 : 20 000 in PBS buffer was added to 
each well and incubated for 1 h. After another washing step, 200 μl substrate solution (TMB) was 
added. For one plate, 22 ml citrate buffer with 8.5 μL H2O2 (30 %) and 550 μL TMB solution were 
mixed and 200 μL were added to each well. Following a 25 min incubation step, the reaction was 
stopped by adding 100 μL of H2SO4 (1 M). Absorbance was measured at 450 nm and referenced 




3.2.4. Protocol of the FPIA  
Running the assay. 120 μL of borate buffer, 40 μL of Milli-Q water (blank) or sample, and 30 
μL of an appropriate dilution of the tracer stock (tracer working solution, TWS) are pipetted into 
each microwell of an 8-well strip and the blank value (mP0) read after a certain tracer incubation 
time (see below). 30 μL of an optimal antibody dilution is added to this mix. After shaking for the 
optimal antibody incubation time (see below), mP is determined. 
Optimization of sensitivity. To find the optimum ratio between antibody and tracer (i.e., dilution 
and volume) to obtain maximum sensitivity at a reasonable signal/noise ratio, to result in a low 
variance. 
This was achieved in 3 steps: 1) First, the amount of tracer was initially set as low as possible with 
a still acceptable signal fluctuation. Intensity and mP is observed over time to select an appropriate 
time.  
2) Next, antibody titration was performed by running the assay with 40 μL Milli-Q water to mimic 
a sample. 30 μL of different antibody dilutions were added to this solution to analyse for tracer 
binding. From the antibody dilution curve the optimal dilution of antibody and tracer were chosen.  
3) Finally, FPIA calibration curves were recorded. Again, 120 μL BB, 40 μL of analyte (standard), 
and 30 μL of the TWS were mixed before 30 μL of the selected antibody dilution was added.  
FPIA is a kinetic assay in which the degree of polarization changes over time, equilibrium is not 
completely reached during the desired short incubation times. Therefore, the time for the tracer to 
equilibrate with the system (tracer incubation time) and the time allowed for competition of the 
tracer and the analyte to bind to the antibody (antibody incubation time) had to be individually 
evaluated and mixing and shaking is very important for the assay reproducibility.  
Initial to all measurements, the mP of the blank (mP0) was determined and later on all mP values 
read divided by mP0. For calibration, the results were plotted against the logarithm of the BPA 
concentrations and to the data points a sigmoidal curve described by a logistic, four-parameter 
equation, was fitted, using Origin 8G Software (OriginLab, Northampton, MA, USA).  
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3.2.5. Lateral flow immunoassay development
3.2.5.1. Conjugation of antibody with gold nanoparticles by passive absorption 
The antibody gold nanoparticles (IgG−GNP) was prepared according to a previously described 
protocol [60, 117]. Purified protein, 80 μL (20 μg) was incubated with 20 ml of gold nanoparticles 
(40 nm) solution (pH 8.5) provided by nanoComposix Europe (Prague, Czech Republic) with stir-
ring for 18 h. After the mixture was stirred for 30 min at room temperature, 1 mL of 10 % bovine 
serum albumin (BSA) solution was added to the stirred solution and stirred for another 60 min at 
room temperature (Figure 19). The resulting suspension was centrifuged (3800 rpm) at 4 °C for 
10 min. Finally, the IgG−GNPs were resuspended with 1 mL of 1 mM sodium borate buffer (con-
taining 1 % BSA, 1 % sucrose,), and stored at 4 °C.
Figure 19. Schematic illustration of conjugation of GNP with IgG by passive absorption
3.2.5.2. Conjugation of antibody with gold nanoparticles by covalent coupling 
The antibody was covalently linked with carboxylated gold nanoparticles by the activated ester 
reaction [72, 118]. One mL of GNP 40 nm was added to 200 mM EDC and 400 mM Sulfo-NHS
dissolved in 1 mL 5 mM PBS, pH 6.0, and stirred and incubated for 90 min at room temperature. 
The activated GNP were isolated from the mixture by centrifugation at 10 °C for 10 min at 3800 
rpm. The pellet was then dissolved in 1 mL of reaction buffer (1 mM BB pH 8.5) and 20 μg of 
IgG per milliliter of solution was added. The mixture was reacted for 2.5 h on a rotary wheel at 
room temperature, and the reaction was quenched by addition of 30 μL of ethanolamine per 1 mL 
of 1 % microspheres for 30 min to deactivate any remaining active NHS esters. The mixture was 
centrifugated at 10 °C for 10 min at 3800 rpm. The supernatant was tested by sandwich ELISA to 
quantify unbound IgG. Then precipitate was resuspended in the blocking buffer (1 mM BB, pH 




3.2.5.3. Preparation of latex particles labelled with antibody by covalent coupling 
The antibody was covalently linked with carboxylated latex microparticles (LMP) by the active 
ester reaction [72, 119, 120]. For this, 100 μL of latex microparticles were added to 1 mL of acti-
vation/coupling buffer (50 mM MES, pH 6.0), then 24 μL of 200 mM EDC and 240 μL of 200 
mM Sulfo-NHS dissolved in latex microparticles solution were added while stirring for 30 min. 
The activated latex microparticles were isolated from the mixture by centrifugation at 10 °C for 7 
min at 14 000 rpm. The pellet was then dissolved in 1 mL of activation buffer and sonicated for 2 
min, followed by the addition of 20 μg of IgG per milliliter of solution. The mixture was reacted 
for 2.5 h on a rotary wheel at room temperature, and the reaction was quenched by addition of 30 
μL of ethanolamine per 1 mL of 1 % latex microparticles for 30 min. The mixture was centrifu-
gated at 10 °C for 7 min at 14 000 rpm. The supernatant was tested by sandwich ELISA to quantify 
unbound mouse IgG in the supernatant. Then the microspheres were centrifugated and resuspended 
in the blocking buffer (50 mM Tris, pH 8.0 with 0.5 % BSA). 
3.2.5.4. Fabrication of lateral flow test strips 
The nitrocellulose membrane is one of the essential parts of a lateral flow device. The reagents 
were deposited onto the nitrocellulose membrane strips using an XYZ piezoelectric printer 
(sciFLEXARRAYER S3, Scienion AG, Berlin, Germany) [121, 122]. The coating hapten-protein 
conjugate BVA-Ahx-BSA was adsorbed on the test line (T) and sheep anti-mouse IgG was ad-
sorbed on the control line (C) (Figure 20).  
According to the literature, the optimum width of testing zones should be around 0.5–1.0 mm [32, 
56]. The lines were made up of several rows of spots spaced at a distance of 250 microns from 
each other. Each spot was formed as a result of the deposition of a number of droplets (each of 
0.35 nL). The number of rows, number of spots per row, and number of droplets per spot varied 
to reach optimal load of reagents in test and control lines. After spotting, the membranes were 
dried at 37 °C for 1 h. 
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The card with membranes was blocked with 1 % casein in PBS for 10 minutes, then washed twice 
for 10 seconds in Milli-Q, and dried 1 h at 37 °C. The card was cut into 3-mm wide individual test 
strips using a cutter Dahle 502 (Novus Dahle GmbH Lingen, Germany). During the experiment, 
several blocking methods and drying conditions were tried, and they will be discussed in section 
4.5. The conjugate pad was treated with 20 mM borate buffer (BB, pH 8.2) containing 1 % casein
and 1 % sucrose and dried at 37 oC for 30 min. The latex microparticles labeled with anti-BPA 
antibodies (IgG−LMP) or gold nanoparticles labeled with anti-BPA antibodies (IgG−GNP) probe 
taken in optimal volume and concentration were added on the conjugate pad. During the experi-
ment, several buffers for treatment of the conjugate pad were tried out and will be discussed in 
section 4.5. All of the above four parts were assembled on a plastic adhesive backing card: firstly, 
the NC membrane was pasted on the center of the backing pad (PVC plate). Then, sample and 
absorbent pads were glued to the bottom and upper section of the adhesive backing pad with a 2-
mm overlap of the NC membrane as shown in Figure 20.
A B
Figure 20. Schematic of the set-up of the developed lateral flow immunoassay for BPA A. The 
LFIA test strip with IgG−LMP B. The LFIA test strip with IgG−GNP
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3.2.6. Measurements and data interpretation of the LFIA
Standard solutions of bisphenol A were prepared from corresponding stock solutions (1 mg/mL) 
in ethanol by serial dilutions in Milli-Q. The test strip was vertically inserted into the wells of a 
microtiter plate with 100 μL of standard solution of BPA or sample. After incubation at room 
temperature for 10 min, the result can already be assessed by the naked eye. A visual assessment 
is convenient for on-site diagnostics since it does not require a special reader device. The disad-
vantage, however, is that this method only provides a qualitative yes/no response. 
The quantitative performance was done by using portable readers and analytical image processing
software to calculate the average signal (intensity) of both the test and control lines (Figure 21.1). 
The instrumental limit of detection (LOD) was calculated as the concentration yielding a signal 
reduction of three times the standard deviation (SD) of the signal for the sample without analyte 
(“blank”); B0 (sample without analyte) minus a value of three times the standard deviation of that 
blank signal (B = B0 − 3 × SD). The dependence of the color intensity on the concentration of BPA
Figure 21.1. Schematic illustration of the peak integration of the test and control line signals. The 
total area of the peak is integrated from the 1.2 mm scanning area. “Line mean” integrates the 
pink area bordered by the line width (black vertical lines) and the red curve dip and the black 
horizontal line whereas “Line max” shows the maximal intensity of the test line at the darkest 
(deepest) part of the line. The red vertical line is a baseline correction.
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(Figure 21.2 A, B) was plotted as calibration curve (Figure 21.2 C). The equation for the calibra-
tion curve approximation (4-parametric sigmoidal fitting) was as in section 2.5.
Figure 21.2. A. Intensity profile of a test and control line and different concentrations of BPA 
spiked as samples. B. Evaluation of different test line signals and baseline correction. C. A cal-
ibration curve obtained by plotting the measured values of the test line intensity versus BPA
standard concentration. The mean and standard deviation (SD) were calculated using results 
from multiple experiments.
The visual limit of detection (vLOD) of the assay was interpreted as the minimal BPA concentra-
tion that caused visible absence of coloration in the test zone in comparison with the nearest lower 
concentration that already shows a colored test line.
Both the opTrilyzer® and the Cube® microreader were employed as detecting devices in the LFIA
experiments for registration and quantification of the color intensity of the control and test lines. 
The Cube® microreader has a cubic shape with an edge length of approx. 41 mm and weighs 40 g.
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Both devices are based on the optical analysis of the LFIA test strips. The preset instrument mode 
of measurement is a colorimetric readout at a wavelength of 525 nm. 
The general elements of the opTrilyzer® and Cube® microreader are: (1) a simple LED serves as 
the light source, (2) the device registers the light reflected by the test surface, and (3) a lens-based 
optical focusing system is employed. The registered image is further processed using software 
tools. The software calculates the analyte content based on the control line and test line intensity 
and gives this information as the result of the measurement. The digital optical registration repre-
sents an image of a test strip as raw data for an array of points arranged in horizontal and vertical 
rows. Each pixel is characterized by three numerical parameters that corresponds to three channels 
of image formation red, green, and blue (RGB) [123]. The registration results for each of the three 
channels are integers that increase as staining intensity increases. 
In the opTrilyzer the signal value ranges from 0 to 800 a.u. with high-resolution imaging capability 
(Figure 22 A). The high-end imaging system (Figure 22 B) can enhance the detection sensitivity 
and the signal can be quantified (i.e., the amount of label) using reader systems because the signal 
intensity is generally proportional to the number of particles captured in the test line (Figure 22
B, C), which also correlates with the amount of BPA. The results are shown on a display and a 
calibration curve can be obtained by plotting the measured test line intensity versus the concentra-
tion of BPA (Figure 22 E).
Figure 22 A. opTrilyzer® reader; B. Working window with image of test strip; C. Working 
window in the opTrilyzer® with optical density profile of the C-line and T-line; D. Test strips 
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with different concentration of BPA; E. Calibration curve (n = 3) for LFIA determination of 
BPA in aqueous samples was obtained by plotting the measured test line intensity versus the 
BPA concentration.
With the Cube® microreader the signal value ranges from 0 to 300 a.u. [123]. The imaging quality 
of the Cube® microreader is slightly inferior to that of the opTrilyzer®, however, it provides the 
intensity profile (optical density (OD) profile) of a test and control line and digitalized results of 
data processing can be accessed through a computer (Figure 23).
Figure 23 A. Cube® microreader. B. working window in the Cube® microreader software with 
image of test strip and optical density profile of the C-line and T-line. C. LFIA test strips with 
different concentration of BPA. D. Converted raw data of optical density of the profiles of T-
lines and C-lines, respectively, into a plot created by Origin software. 
It should be noted that the disadvantage of dealing with those test strip images inserted into readers 
may result in low reproducibility of the results. The reasons causing this effect is firstly the posi-
tioning error which comes from the relative positions of the test inside the reader that affects the 
control bands during printing of capture molecules (control and test line) onto the strip membrane. 
The second positioning error (Figure 23 C) is cutting of the membranes that can result in slightly 
different lengths. The third positioning error is that the strips can be positioned a little bit to the 
right or to the left relative to the reading window and the cassette housing. The uncertainty of the 
positioning of the strip in the reader results in an unstable baseline. For statistically reliable results 
based on a large amount of samples, this simple reader is unsuitable due the large resulting standard 
deviation.
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An alternative approach for quantification of the color intensity of test and control lines is image
processing software. The digital imaging of LFIA strips were processed with the image analysis 
software Gwyddion v2.19 (Figure 24) [124, 125]. It works with 48-bit images – from 0 to 65,535
range of intensity values (shades of grey) – and automatically calculates the value in area under 
study which ensures an automated quantitative analysis of the images and is therefore user-
friendly. A gray scale optical analysis was performed from photographed images by Canon EOS 
750D (Canon, Japan) under an LED ring lamp (AIXPI, China), where an area of the size 8 × 1.2 
mm was selected for the analysis of each image (Figure 24 A). The program has a function of 
automatically smoothing the data (Figure 24 B, C). The data can directly be transferred as one file 
to Origin.
In contrast to the ImageJ® free image processing software (ImageJ, National Institute of Health; 
Bethesda, Maryland, USA), the software Gwyddion allows for a quick processing of large amounts 
of test strips because of the implemented algorithms for data analysis. ImageJ does not provide 
these functions and data processing can only be done manually by using, for example, the software 
Origin.
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Figure 24. Screenshot from the Gwyddion software and its use for the quantitative assessment of 
LFIA results. A. Test strips with different concentration of BPA. B. Raw identification data of the 
control and test lines and assessment of its optical density profiles. C. Normalized identification data 
by the software of the control and test lines and assessment of its optical density profiles. D. Con-
verted Gwyddion raw data of optical density of the test lines and control lines profiles transferred 
into a template of the data analysis software Origin™. 
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IV. RESULTS AND DISCUSSION
4.1. CHARACTERIZATION OF THE HAPTEN-PROTEIN-CONJUGATES
Indirect immunoassays for small molecules require as competitor a hapten-protein conjugate that 
is immobilized on the solid phase and acts as competitor in this competitive immunoassay format. 
Protein conjugates often use bovine serum albumin (BSA) as the protein part since it is inexpen-
sively available in high purity and can be coated directly to microtiter plate well surfaces. 
For the development of highly sensitive and specific immunoassays, it is important to design a 
proper hapten structure. Two basic approaches were used for design and synthesis of BPA haptens. 
One strategy of these approaches was aimed to preserve the two phenolic groups as the potential 
immunodominant epitope in a homologous approach. The other, heterologous, approach is based 
on the fact that in a competitive format it would be expected that assay sensitivity can be improved 
by increasing antibody affinity towards the analyte over the hapten-protein conjugate competitor 
that here differs more in structure than in the homologous format [94]. 
In the first approach, the commercial bisphenol valeric acid (BVA) was used as a hapten, protein, 
i.e., BSA, conjugation was achieved – as in the immunogen – via the carboxyl group of BVA,
leaving the two phenol groups free for the immunorecognition. The antibodies that were raised
against this hapten [126] were expected to recognize the two phenolic groups. In the second ap-
proach, 6-aminohexanoic acid (Ahx), a linker with six carbons as a spacer, was used for the first
time in the synthesis of a BVA hapten-protein conjugate. It was introduced to give more flexibility
and to give rise to greater affinity differentiation between the analyte and a competing hapten by
the antibody. The results indicated that the coupling of the haptens to BSA was successful.
4.2. DEVELOPMENT AND OPTIMIZATION OF THE INDIRECT ELISA
After preparation of the conjugate, the indirect competitive ELISA was optimized by checkerboard 
titrations. The optimal concentration of the primary antibody for BVA-BSA was 9 ng/mL, and for 
BVA-Ahx-BSA 7 ng/mL, the dilution of BVA-BSA was 1: 550 000 and of BVA-Ahx-BSA 1: 600 
000 and the optimal dilution of goat-anti-mouse HRP was 1: 20 000. Figure 25 shows that the 
lower IC50 value was obtained with the BVA-Ahx-BSA conjugate. The results revealed that the 
hapten-protein conjugate including a C6 spacer displayed satisfactory precision and sensitivity with 
an IC50 of 0.2 μg/L. The lower the value of IC50 the more sensitive measurements are possible.   
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Figure 25. Calibration curves obtained for optimized conditions with the two conjugates (BVA-
BSA, BVA-Ahx-BSA). Parameters of the 4-parameter fitting are shown in Table 5. 
Table 5 Parameters of the 4-parameter fitting of the calibration curves of Figure 25. 
In our study, the pair IgG with BVA-Ahx-BSA yield better sensitivity than with BVA-BSA system 
(Table 5) (Figure 25). BVA-Ahx-BSA was chosen for future characterization and validation of 
assay performance. The “precision profile” [85] was plotted for the assay with BVA-Ahx-BSA 
conjugate, which provides information to reliably calculate the value of the LOD and the limits of 





BVA-BSA 1.09 0.02 0.4 0.99 0.08 
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Figure 26. ELISA calibration curve with conjugate BVA-Ahx-BSA (red solid line), precision 
profile (blue squares and cyan line), and measurement range (indicated by green arrows) from 
0.05 to 8 μg/L (intersection points at 30 % relative error of concentration, solid black lines). 
A relative error of the determined concentration of 30 % was considered acceptable to mark the 
limits of detection (LOD). A lower limit of detection of 0.05 μg/L and an upper limit of detection 
of 8 μg/L was determined, the measurement range spanning over more than 2 decades. 
4.3. FPIA: SELECTION OF OPTIMAL TRACER-ANTIBODY COMBINATION AND CHARACTERIZA-
TION
The combination of tracer and antibody has a significant influence on sensitivity, selectivity, and 
reliability of an FPIA, and should always be carefully studied. In this work, new tracers were 
synthesized. The strategy for tracer synthesis, namely to use the amino group in AMF and coupling 
BVA via its carboxylic acid group, especially compared to using, in two cases, 6-aminohexanoic 
acid (6-Ahx) as spacer, was to study the influence of tracer structure on the assay sensitivity in 
FPIA [127, 128].  
Fluorescence polarization was determined on a Sentry 2000Si, a multi-well fluorescence polariza-
tion instrument equipped with a ceramic fluid metering system pump for automated reagent 
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dosage. The light source is an LED with 485/535 nm filter set and a 510 nm dichroic mirror. 
Reactions are read in black medium-binding 8-microwell Fluorotrac strips.  
The intensity of the blank (borate buffer) on the instrument was about 37 000 in both orientations 
(I║ and I ). FP is close to zero (0 mP). When a tracer dilution of 1: 10 000 is added, intensity 
reading rises to ca. 200 000. This approx. 5-fold increase is a prerequisite for stable readings with 
the instrument and can be achieved by increasing the tracer concentrations. In any case, signal 
development must be observed and the optimal tracer incubation time, before the addition of the 
antibody, determined. This resulted in waiting times of 2.5 to 6 min. Tracers are stable on storage 
and benefit from the ability of fluorescein to fluoresce with high quantum yield while retaining the 
immunoreactivity of the antigen. But, since the tracer working solution is a dilution of the tracer 
in the buffer, it is not very stable to elevated temperatures, pH and it is light sensitive [129]. It was 
found that tracer working dilutions must be freshly prepared every day.  
When the antibody is added and mP determined, a tracer that effectively binds to the antibody, 
leads to a strong decrease in mP with increasing dilution of the antibody (antibody titration) in a 
sigmoidal course (Figure 27). When the tracer cannot bind to the antibody, no change with anti-
body concentration is observed. According to the antibody dilution curves in Figure 27, the two 
tracers synthesized bind to the antibody. The optimum dilution of the antibody can be obtained 
from the antibody dilution curves in Figure 27; it corresponds to approximately 50 % of the max-
imum signal (Table 6). Higher dilutions result in too small signal changes, lower dilutions waste 
antibody. Optimum dilutions were in the range of 1: 100 to 1: 20 000. 
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In FPIA, antibody binding is kinetically controlled, thus the time until measurement after adding 
the antibody must be optimized individually (Table 6). 
The tracer structure could significantly influence the immunoassay performance. As shown in Ta-
ble 7, the spacer Ahx (C6) plays an important role in the binding reaction, higher sensitivity was 
observed by using the BVA-Ahx-AMF tracer (IC50, 7.5 μg/L) and BVA-AMF (IC50, 33.4 μg/L). 
The selection of the optimal tracer was based on the parameters of assay IC50 and LOD. This phe-
nomenon has been confirmed in other studies [40, 130, 131]. Therefore, the tracer BVA-Ahx-AMF 
was finally selected for further studies (Figure 28). 
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Figure 28. Calibration curves obtained for optimized conditions with the two tracers (BVA-
AMF, BVA-Ahx-AMF). Parameters of the 4-parameter fitting are shown in Table 8. 
Table 6. Characteristics of the binding of the two tracers to the monoclonal anti-BPA anti-
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Calibration curves with precision profiles for the FPIA with BVA-Ahx-AMF was determined un-
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Figure 29. FPIA calibration curve with conjugate BVA-Ahx-AMF (red solid line), precision 
profile (blue squares and cyan line), and measurement range (indicated by green arrows) from 
2 to 155 μg/L, determined via intersection points at 30 % allowed relative error allowed relative 
error of the determined concentration (black line).  
4.4. INVESTIGATION OF MATRIX EFFECTS IN ELISA AND FPIA 
One of the important parameters for the optimization of immunoassays is the evaluation of the 
influence of matrix components, which can interact in a variety of ways with the components of 
an immunoassay. Matrix compounds are mainly dissolved salts, organic solvents (from 
Table 7. Parameters of the 4-parameter fitting in the developed FPIAs using different tracers. 
 




BVA-AMF 1.0 0.4 33 0.99 11 




extraction), and endogenous disturbances, e.g., humic acids or proteins, which vary in different 
samples. This “matrix effect” is a common problem for the immunoassay, which could reduce the 
sensitivity and reliability of the competitive immunoassay. Usually, interferences are quantified 
by comparing a standard curve produced in a blank matrix (e.g., ultrapure water) with a calibration 
curve generated in the sample matrix. If the two curves are coinciding when superimposed, the 
effect of the matrix is not significant, hence, the samples can be analyzed using the standard curve 
prepared in the matrix blank [132]. 
In this study, the effect of 5 % acetone, 5 % methanol, 10 % methanol, 3.5 % sodium chloride and 
hard water with 7 degrees of German hardness (°dH), 14 °dH and 21 °dH were investigated (1 °dH 
corresponds to a quantity of 10 mg of calcium oxide per liter of water). The spiked solutions were 
analyzed by ELISA and by FPIA. As shown in the Table 8 and Figure 30, an ELISA in the pres-
ence of methanol, sodium chloride, and acetone, still showed high sensitivity (low IC50), but the 
signal (A1) was lower than that of the standard curve without matrix. It is possible to dilute the 
samples multiple times by which it could be possible to lower the matrix effect. 
 























Figure 30. ELISA standard curves for BPA detection using different matrices (n = 3) 
 
53 
It was also interesting to observe that the ELISA signal (A1) and sensitivity (IC50) were consider-
ably enhanced when the Ca2+ concentration was increased (data shown Table 8 and Figure 30). 
To lower the matrix effect of calcium a high-salinity buffer is preferably used. 
Compared with ELISA, it was interesting to observe that with the FPIA, as shown in Figure 31 
and Table 9, the value A1 and the sensitivity (IC50) were considerably enhanced with the matrix 
present, which is very likely a result of the quite high buffering capacity of BB used as working 
buffer. However, to prevent false negative results due to matrix interferences, in the case of the 
FPIA it was possible to dilute the samples multiple times by which it was possible to lower the 
matrix effect.  
Table 8 Parameters of ELISA for BPA in different matrices 
A1 A2 IC50 B (Slope) R² 
Reference curve (STD) 0.96 0.05 0.2 0.99 0.99 
Ca2+  21 °dH 0.8 0.04 0.02 0.87 0.98 
Ca2+  14 °dH 1.01 0.04 0.06 0.7 0.99 
Ca2+  7 °dH 0.68 0.05 0.02 0.97 0.99 
NaCl 3.5 % 0.11 0.04 0.03 0.84 0.99 
Acetone 5 % 0.6 0.04 0.1 0.88 0.98 
MeOH 5 % 



































Figure 31. FPIA standard curves for BPA detection using different matrices (n = 3) 
 
Table 9. Parameters of FPIA detection of BPA in different matrix. 
 A1 A2 IC50 B (Slope) R² 
Reference curve (STD) 1.0 0.4 7.52 0.69 0.99 
Ca2+   7 °dH 0.93 0.4 0.48 0.78 0.99 
Ca2+   14 °dH 0.94 0.4 1.6 1.1 0.99 
Ca2+    21 °dH 1.1 0.5 1.1 1.1 0.99 
NaCl 3.5 % 0.9 0.2 1.1 1.2 0.99 
Acetone 5 % 0.8 0.2 0.4 0.57 0.99 
MeOH 5 % 















4.5. OPTIMIZATION OF ANALYTICAL PARAMETERS OF LFIA  
4.5.1. Determining optimal concentration and pH for antibody conjugation 
The central reagent in lateral-flow immunoassays (LFIA) are antibodies that “carry” particles that 
upon their deposition in dedicated zone form “lines” (T and C lines) that are visible to the naked 
eye. To establish such an assay, the particles, e.g., gold nanoparticles (GNP) have to be “decorated” 
with the analyte-selective antibody (IgG). Several methods have been studied. 
For conjugation of gold nanoparticles and antibody by passive absorption, the optimal pH and a 
minimum amount of antibody for a stable GNP reagent [133, 134] had to be found. To determine 
the minimum amount of IgG and the most appropriate buffer for conjugation of gold nanoparticles, 
the electrolyte 10 % sodium chloride, added to several buffers with ionic strength 1 mM containing 
different amounts of IgG, was chosen. If no antibody is present, the addition of NaCl would cause 
gold particle coagulation. The titration was executed in a flat-bottom 96-well non-binding micro-
plate. Firstly, the same amount (200 μL) of 40 nm gold nanoparticles was added into the wells. 
Then 20 μL of different concentrations of IgG was added in order to obtain concentrations of 300 
μg/L – 3 μg/L,  respectively, in different buffers: Milli-Q water (from row A1-3 to H1-3) pH 7 , PBS 
pH 7.5 (A4-6-H4-6), borate buffer (BB) pH 8.5 (A7-9-H7-9), carbonate buffer (CB) (A10-12 – H10-12) 
pH 9.6, and incubated for 1 h on a plate shaker at 750 rpm. After incubation, 20 μL of 10 % NaCl 
solution (in Milli-Q water) was added to every well and incubated for 10 min, then OD280;520;800 
was measured for each mixture in different wells after the color change was completed. The well 
positions which remained red demonstrated successful formation of a gold-antibody conjugate, 
where the antibodies protect the gold nanoparticles from the salt and hence from aggregation. The 
positions that turned blue have aggregated gold particles in them and those mixtures do not have 
enough antibody to protect the gold nanoparticles from aggregation salt. This is shown in Figure 




























Figure 32 A. The wells of an MTP turned blue when aggregated gold particles formed in it. 
Upon successful conjugation, the wells remained red. B. Concentration dependence of GNP 
(optical density at 580 nm) after adding different concentrations of anti-BPA IgG in different 
buffers.
In the experiment, according to the calibration curve (Figure 32 B), 7 μg of IgG in carbonate and 
borate buffer were found to be the minimum amount of IgG and suitable buffers for stabilization 
of the gold. However, we selected 20 μg and borate buffer for conjugation, because, in this study,
7 μg of IgG and carbonate buffer often caused coagulation of GNP during the conjugation.
After a successful conjugation of gold nanoparticles with 20 μg of anti-BPA IgG in different buff-
ers (PBS, BB, CB), the stability was confirmed by UV-Vis spectroscopy. Figure 33 A, B show 








Figure 33. UV-Vis spectra and photograph of GNP conjugates. A. The UV-Vis spectra from the 
conjugates in borate buffer, carbonate buffer and PBS coupled with 20 μg of antibody. The blue 
line represents aggregation of the conjugate. B. Plastic tubes with GNP turned to blue having ag-
gregated gold particles in it. Succeeded conjugation is in the tube remaining red.   
It was confirmed that PBS buffer is not a suitable buffer for conjugation. The PBS buffer used 
contained approximately 0.14 M NaCl, which is higher than the biological salt concentration of 
about 0.10 M. Borate and carbonate buffers do not contain sodium chloride and have optimum pH, 
which provides the net charge of the protein is zero or slightly negative. This prevents the aggre-
gation of the protein owing to electrostatic attraction while maintaining the hydrophobic interac-
tions and facilitates the conjugation of the antibody to the gold.  
4.5.2. Determination of coupling ratio of particles with antibody by sandwich ELISA  
The coupling ratio of gold nanoparticles (and the later used latex microparticles) to antibody (IgG) 
is an important factor that can influence assay sensitivity. Too many antibodies would reduce the 
sensitivity of the LFIA, and too few IgG would cause incomplete coupling, leading to a weak 
intensity band of the T-line, which would be adverse to the detection limit. Numerous studies have 
used various methods to measure the amount of protein attached to a nanoparticle surface [135–
137]. 
In this study, a sandwich ELISA to quantify mouse IgG in the supernatant was developed. The 
absolute concentration of antibody adsorbed onto the GNP and latex was inferred to be the mass 
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difference between the antibody added to the gold nanoparticles (GNP) and latex microparticles 

















Figure 34. Calibration curve of the sandwich ELISA for determination of mouse anti-BPA IgG 
in supernatant.  
 
From the ELISA calibration curves (Figure 34), it was found that 56 % of IgG was coupled with 
GNP by covalent coupling. It was also found that 49 % of IgG was adsorbed onto GNP by passive 
absorption when using borate buffer. By using carbonate buffer, only 40 % of IgG was attached to 
the GNP. By using PBS, the amount of IgG attached to the GNP was reduced to just 25 %. It 
appears that the convenient and highly affordable method of coupling GNP with IgG by passive 
adsorption using borate buffer works sufficiently well. A study of incubation times showed that 
for passive absorption an optimal incubation time with IgG was 18 hours. 
4.5.3. Membrane selection for LFIA  
The individual type of nitrocellulose membrane chosen is one of the most significant factors that 
influence the protein binding level, mobility of reagents, testing time and sensitivity of a LFIA test 
[121, 138]. The combination of the type of membrane and the immobilized reagent should be 
appropriate to ensure optimal loading of hapten-protein conjugate (test line) and secondary anti-
body (control line) on the surface of the membrane, available for specific interaction with the an-
tibody-particle probe. Moreover, the particle size is another important factor that influences the 
flow rate. Capillary rise of larger gold nanoparticles (≈ 40 nm) through lateral flow membranes 
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was slower than for smaller ones (≈ 20 nm) [73, 139]. The 300 nm latex microparticles is 20 times
brighter in visibility per particle than traditional 40 nm gold in LFIA [32]. It provides greater con-
trast against the white background of a lateral flow membrane than colloidal gold [31]. It is im-
portant that for any OD per volume, there are about twenty times less particles, so conjugate vol-
umes will need to be adjusted. As a starting point, increasing OD or conjugate volume per strip 
two-fold will give a boost in sensitivity, because they are of blue color (good visibility for eyes 
and devices) and 300 nm in size and their mobility was sufficiently decreased. Several studies[55, 
70, 74, 119, 140, 141] had shown that decreased mobility of larger particles resulted in better assay 
sensitivity, because it leads to longer incubation times of the reagents.
Figure 35. Conjugate band width as a function of liquid contact zone and photographs of differ-
ent nitrocellulose membranes with latex microparticles spotted equidistantly onto the membrane.
The mobility of microparticles on a membrane also depends on its pore size and its so-called
“wicking” times. The available NC membranes are characterized by different pore sizes (8 – 15 
μm), protein binding capacity (low-medium-high) and by the wicking time (100 – 200 sec), see
Table S 2. All these characteristics may influence the response time, intensity and sharpness of 
the signal, and resultant sensitivity and reproducibility of the test. Figure 35, Supplementary ma-
terial Figure S 9, S 10, and Supplementary material Table S 2 summarize the experiments per-
formed on the interaction of the IgG−LMP and IgG−GNP probes with the coating conjugate BVA-
Ahx-BSA, deposited in the test zone of various types of membranes. The photographs show that 
the most contrasting and brightest reaction zone depends on both the pore size/flow rate of the 
Membrane CNPC 15 Membrane CNPC 10 Membrane CNPC 8





membrane and the molecular weight of the protein conjugate (IgG: 150 kDa, BVA-Ahx-BSA: 72 
kDa) (Table 10, Table S 2).
Table 10. The specific interaction of the antibody-latex probe on different types of membranes.
Membrane characteristics* Microphoto images of interaction with anti-mouse IgG 













CNPF 8 low 170 ± 25
CNPF 10 low 125 ± 25
CNPC 12 medium 120 + 28
CNPC 15 medium 100 ± 25
CNPH-N ND high 70 ± 20
CNPH-N ND high 90 ± 35
* Characteristics are provided by manufacturer. ND – not disclosed
It may be summarized that binding capacity was not a critical factor for the quality of visibility of
the test line, whereas little pore size 8 and 10 μm and the larger molecular weight of IgG (150 
kDa) in comparison with BVA-Ahx-BSA (72 kDa) (Table 10 and Table S 2) appeared to be suf-
ficient for better surface fixation and availability for binding with the relatively large latex probe 
(Ø = 300 nm) and gold nanoparticles (Ø = 40 nm). It is likely that high pore size promotes deeper 
and more widespread penetration and fixation of coating antigen.
In this regard, the latter was not available for the IgG−LMP and IgG−GNP probe. This effect 
became more critical for the conjugates with smaller molecular weight, for example with OVA 
(ovalbumin, MW 42.8 kDa). Consequently, a better visual effect was achieved when a larger mo-




smaller pore size (8−10 μm). Additionally, the size of the particles has an influence on migration 
speed through the NC. It was found that NC membranes with a pore size of 8−10 μm are suitable 
for 40 nm IgG−GNP. NC membranes with pore size 10 μm are suitable for 300 nm IgG−LMP. 
The NC membrane with 10 μm provides an optimal visibility of the test line and ideal migration 
speed of the particles (IgG−GNP and IgG−LMP).  
4.5.4. Membrane blocking and test duration 
The migration of sample and IgG−LMP/IgG−GNP probe through a membrane is affected by their 
non-specific interactions with NC membrane due to its sorption capacity. To prevent unwanted 
interactions of test reagents, a membrane blocking was evaluated [142]. Several blocking solu-
tions, such as Milli-Q water or PBS buffer containing or 1 % Casein, 1 % BSA, or 0.1 % gelatin, 
were examined in the study (Table 11, Table 12). The optimal blocking solution appeared to be 1 
% casein, the speed of signal development was rather fast, then 1 % BSA/PBS. It was found that 
blocking of the NC membrane with 1 % casein and 0.1 % gelatin provided comparable migration 
speed unlike to 1 % BSA blocking which resulted in slower mobility of antibody−latex micropar-
ticles and antibody–gold nanoparticles. Interference from anti-carrier antibody interaction with 
BSA could result in such an effect, so BSA was excluded from blocking agents. It is noteworthy 
that a 1.5-fold increase in membrane pore size (from 8 to 12 μm) accelerated the test by 1.5 times, 
regardless of the blocking formulation. 
 Table 11. Influence of blocking agents on migration speeds of IgG−GNP. 
N Membrane type 
Pore size, 
μm 
Flow time (sec) in 2.5 cm-membranes blocked 
with Wicking time 1 % Casein 1 % BSA 0.1 % Gelatin 
1 CNPF 8 400 500 480   Slow 
 
 
  Fast 
2 CNPF 10 240 360 270 
3 CNPC 12 200 430 250 
4 CNPC 15 150 330 200 
 
Table 12. Influence of blocking agents on migration speeds of IgG−LMP. 
N Membrane type 
Pore size, 
μm 
Flow time, sec,  
in 2.5 cm-membranes blocked with Wicking time 1 % Casein 1 % BSA 0.1 % Gelatin 
1 CNPF 8 600 1100 660   Slow 
 
 
  Fast 
2 CNPF 10 440 800 470 
3 CNPC 12 400 730 440 





Thus, the blocking of membrane surface with 1 % casein solution was optimal to avoid non-spe-
cific binding and control the flow rate as well as to stabilize reagents in the test and control lines 
but decreased the mobility of reagents through the membranes.  
The compensating acceleration was achieved by choosing membranes with 10 μm pores for 
IgG−LMP and 8 μm pores for IgG−GNP.  
4.5.5. Composition of the detection reagent mixture on the conjugate pad  
In order to improve solubilization of IgG−GNP or IgG−LMP, prevent aggregation, and to provide 
an appropriate test line formation with an adequate migration rate, different reagents are often used 
as additives on the conjugate pad. Those additives are used for protein stabilization on a dry matrix. 
It should be emphasized that the choice and concentration of a surfactant was an important factor 
influencing assay performance [60, 75, 141, 143].  
Seven kinds of conjugate pad (SureWick® GFDX, SureWick® G027, SureWick® G041, PT-R1, 
PT-R5, PT-R6, PT-R7) (Table 3) were tested. 
Moreover, in combination, several blocking solutions were tested: 
(A) 25 mM BB, 0.5 % BSA, 0.5 % Tween 20, pH 8, 10 % sucrose, 5 % trehalose 
(B) 25 mM BB, 1 % BSA, 10 % sucrose  
(C) 25 mM BB, 1 % BSA, 10 % sucrose, 5 % trehalose 
Five μL of blocking solution was pipetted onto the conjugate pad and dried at 37 °C for 60 min. 
Then GNP-IgG or latex-IgG was pipetted onto the conjugate pad with the pipette, 5 μL per strip, 
and again dried at 37 °C for 60 min. 
Using BB without any additives resulted in low sensitivity and weak color (Table 13). The optimal 
conjugate pads were previously blocked with solution C (25 mM BB, 1 % BSA, 10 % sucrose, 5 
% trehalose) (Table 13). 
Application of this mixture resulted in improved color intensity, optimal flow rate and enhanced 
test sensitivity. There was also a good solubilization of the detector reagent from the conjugate 
pad and a better protection of IgG−GNP or IgG−LMP. Application of this mixture resulted in 




Table 13. Influence of blocking agents on the intensity of the test line.
A conjugate pad with a good hydrophilicity and release efficiency promises the favorably fast
release of the gold nanoparticles conjugate and latex microparticles conjugate. The best perfor-
mance according to the color intensity of the test line was found for the gold conjugate pad PT-5. 
For the latex conjugate, the pad SureWick® G027 was chosen for the following experiments. It 
was found that conjugate pads with treatment provided better stability of the particles, and the 
repeated experiment with 2-year-old strips provided comparable results (Figure 36). 
Figure 36. Reproducibility study: a sample spiked with 0.01 μg/L BPA was applied to the LFIA 
strips with IgG−GNPs. A. freshly prepared strips (n = 3). B. 12 months old strips (n = 3). C. 24 
months old strips (n = 3) processed using the Gwyddion software combined with a fit using Origin™.
The standard deviation is in the range of 0.5 – 0.80 %
Without 
treatment
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4.5.6. Optimization of spotting conditions and reagent application 
Appropriate amounts of detector reagent, antibody-particle probe, and coating reagent, BVA-Ahx-
BSA, had to be concurrently optimized to get the highest sensitivity of detection. Moreover, an 
optimal concentration of capture control reagent (anti-mouse IgG antibody) had to be found for 
the formation of adequate color intensity in the control zone.  
As known from the principles of competitive assays, higher concentrations of the reagents promote 
a high signal but decrease the sensitivity of the assay [144]. Thus, the task of optimization for 
development of a sensitive competitive assay means possible minimization of reagent amounts 
keeping well-visible reaction zones. The resultant color intensity of the test line was registered as 
a maximal peak value of summarized optical density and depended on multiple factors.  
In order to create lines using a non-contact spotter, solutions were arrayed with 350 μm and 250 
μm spot to spot pitch (Table 14). It was found that the distance between the spots with 350 μm 
spacing is too wide and this may lead to inaccurate results during interpretation of results with the 
cassette readers opTrilyzer® and Cube®.  
Table 14 Influence of spot pitch on the image of the test line. 




The loading of the coating conjugate per strip could be regulated by the concentration of the coat-
ing conjugate solution to be applied, by solution volume calculated in microdroplets, and the ap-
plication area. The loading of antibody per strip varied during IgG−LMP or IgG−GNP probe prep-
aration and depended on the amount of probe deposited in the sample pad. 
In the study, the overall loadings of coating antigen as well as antibody loading were decreased by 
a factor of 5, so the resultant maximal value of optical signal became 2.5-fold lower, from 500 to 
100 units. However, due to the reduction in the working area of test zone from 75 to 30 spots, the 
mean color intensity of an individual spot remained the same (2.65 units). This allowed for im-
proving the limit of BPA detection 100-fold without loss of visual quality. However, for visual 




Table 15. Optimization of reagent load and test strip characteristics for BPA detection. 



























40 // 14 nL 5 × 15 0.96 40 5.0 500 6.7 1000 
40 // 14 nL 5 × 15 0.96 40 2.5 400 5.4 250 
20 // 7 nL 5 × 10 0.44 20 2.5 350 11 25 
25 // 
8.75nL 3 × 10 0.2 20 2.0 250 
8.3 10 
        


























40 // 14 nL 5 × 15 0.96 40 5.0 450 6 1000 
40 // 14 nL 5 × 15 0.96 40 2.5 220 3.0 250 
20 // 7 nL 5 × 10 0.44 20 2.5 160 5.0 25 
25 // 
8.75nL 3 × 10 0.2 20 2.0 100 2.65 10 
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LFIA strip test image of BPA, μg/L
IgG−GNP
LFIA strip test image of BPA, μg/L
IgG−LMP
Figure 37. Determination of BPA in LFIA strip test, visual LOD (in red)
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4.5.7.  Analytical characteristics of the of LFIA
The results of the LFIA test strip can be evaluated both visually and with a device that scans the 
test zone and registers its color intensity. Digitization of the color intensity in the test zone using 
a strip reader allows quantifying the reaction by pre-calibration. Moreover, the limit of detection 
determined by instrumental readout is much lower than the cut-off estimated by naked eye. The 
LOD is calculated from the standard curve and defined as the concentration that corresponds to 
the mean intensity of the blank test line value minus 3×SD of the blank [145−147]. Alternatively, 
for convenience, LOD is taken as IC20, and the measurement range is taken as IC20 – IC80 (Figure 
38, Table 16). 
The intensity of test line color was converted into digital units by a strip-scan reader and used for 
plotting of the standard curves. The corresponding BPA standard curves are shown in Figure 38.






































Figure 38. BPA standard curves (A. IgG−GNP and B. IgG−LMP). Parameters of visual and 
instrumental detection of BPA in the developed LFIA of BPA. Test and control lines are visible and 
scanned using the opTrilyze® reader, a handheld device, and number plotted with Origin™.
Table 16. Parameters of visual and instrumental detection of 
BPA in the developed LFIA.
Particles Visual cut-
off, μg/L
IC50, μg/L IC20 (LOD), μg/L
GNP 10 1.2 0.2




4.5.8.  Influence of matrix interference on the sensitivity of the LFIA 
In this study, the influence of organic solvents on the standard BPA curve was tested with Milli-
Q containing 0 %, 10 %, 30 %, 50 %, and 80 % of methanol, or 5 % of acetone. The influence of 
water mineralization was tested by assaying water with 3.5 % sodium chloride (simulating marine 
water) and Ca2+/Mg2+ levels simulating hard water with 7 °dH (“Grad deutscher Härte”, degrees 
of German hardness), 14° dH and 21° dH. It was demonstrated that 5 % acetone, 3.5 % sodium 
chloride and hard water with 7 °dH, 14° dH and 21° dH did not affect the assay performance.  
The action of methanol resulted in a decrease of color intensity due to the deterioration of probe 
release from the conjugate pad and inhibition of antibody binding in an organic solvent medium. 
Thus, staining in the test and control zones of the membrane at 80 % methanol was not observed 
at all. At 50 % methanol, the IgG−LMP color development remained rather weak compared to the 
Milli-Q reference. With IgG−GNP the test and control zones of the membrane was not observed 
at all. At 30 % methanol, the color development was weaker compared to the test performed with 
BPA standards in Milli-Q due to the IgG−GNP probe not being released completely. Full dose-
response curves were obtained at 30 % share of methanol, however, an acceptable level of color 
intensity was only reached when methanol content was decreased to 10 %. The methanol content 
in pretreated samples was adjusted to 10 %. A slight left-shift of the calibration curve of calibrators 
in 10 % MeOH was observed in comparison with the curve generated in Milli-Q (Figure 39). 













































Figure 39. The influence of methanol concentration of 10 % compared to the standard curve 
obtained from calibrators in Milli-Q with A. IgG−GNP and B. IgG−LMP conjugates for BPA 




4.5.9.  Cross-reactivity of the antibody  
Cross-reactivity in aqueous solutions of various structural analogues of BPA was evaluated. Some 
compounds that are, apart from bisphenol A, present in food contact materials, plastics, or thermo 
paper, display structural similarities to bisphenol A. These compounds were therefore studied for 
cross-reactivity behavior. The results for different compounds are summarized in Table 17. 
Compounds with a similar structure as bisphenol A showed cross-reactivity that varied according 
to the used method (FPIA, ELISA, and LFIA). Removal of central methyl groups and of the hy-
droxyl groups of the bisphenol A molecule resulted in a strong reduction in cross-reactivity, while 
the extension of the methyl group by an additional carbon in the case of bisphenol B (BPB) resulted 
in a cross-reactivity of about 200 %. This remarkably high cross-reactivity for this particular com-
pound can be explained by the higher similarity of the compound to the antigen used for immun-
ization. That antibody was probably produced from BVA directly coupled to a carrier protein to 
obtain an immunogen. However, more complex bisphenol A analogues, such as bisphenol S (BPS), 
were not recognized (CR < 0.1%). When structurally simpler phenolic compounds, such as 4-
octylphenol (OCP) and 4-nonylphenol (4-NP) were detected, the color of the test line in the LFIA 
strip appeared to be of the same intensity as that of the negative control sample. Therefore, the test 
was specific for BPA and showed “no” (< 0.1%) cross-reactivity to OCP and 4-NP and no signif-
icant cross-reactivity was observed by ELISA and FPIA.  
There was some disagreement between cross-reactivity of structural analogues determined by 
FPIA and indirect ELISA. This was previously reported. Xu et al. [148] and Kolosova et al. [149] 
also found different CRs using FPIA and indirect ELISA. We assume that this behavior is deter-













































































































































































































































4.6.  DETERMINATION OF BPA IN POLYMER MATERIALS AND PRODUCTS  
After assay development, the test systems of LFIA, FPIA and ELISA have been optimized to the 
extent in which the analytical methods are also suitable for real samples.  
Bisphenol A affects us in everyday life through contact with polymer products, for example, by 
wearing sunglasses made of plastic through dermal contact, using CDs, using phones with glass 
screen protector, transport tickets, etc. Children (and some adults as well) like to share the bath tub 
with a rubber duck, a very popular bath toy. But warm water at bath time can cause BPAs to leak 
into the water [137]. From paper used in thermal printers, used in cashier receipts, BPA can be 
transferred to other products or absorbed through the skin of consumers’ hands or the hands of 
those who operate with the paper [144–147]. That’s why in this work bisphenol A release from 
various different plastic samples was analysed by the optimized and improved test systems FPIA, 
LFIA and ELISA.  
Taking into account that BPA is a ubiquitous environmental contaminant [150], six wastewater 
samples were obtained from three different wastewater treatment plants from Berlin (Ruhleben) 
and Brandenburg (Schönerlinde, Waßmannsdorf). The samples were first filtered through folded 
paper filters and then through glass-fibre syringe filters. Influent samples were diluted 1:100 with 
Milli-Q water before analysis, and effluent samples 1:10. None of them tested positive for BPA 
by any of the immunoassays and LC-MS. 
Thermal paper samples (n = 3) were collected from local supermarkets of different countries, Ger-
many (Berlin), Belgium (Brussels), and Russia (Moscow). Other paper products (n = 9) were col-
lected mainly in Berlin in 2018. These samples were grouped into 3 categories: flyers (e.g., adver-
tisement brochures from local restaurants), tickets (e.g., train tickets), food contact papers.  
The analyzed samples were representative of various brands of rubber duck toys, CDs, sun glasses, 
phone glass screen protector available in a local EuroShop in Berlin, Germany. 
4.6.1.  Sample preparation  
In order to obtain the best analytical methods for the examination of plastic samples, polycarbonate 
cubes were tested. Since polycarbonate is synthesized from bisphenol A, it could have gone for 
sure that the examined polycarbonate cubes contained bisphenol A. Eight different methods have 




the highest yield of bisphenol A was subsequently used to determine the concentration of real 
plastic samples [30, 78, 95, 153–158]. The execution of this extraction is shown in Figure 40. 
 
Figure 40. Scheme of sample preparation 
The entire polymer was dissolved in dichloromethane and partially decomposed into the mono-
mers. Other substances contained in the solution were precipitated by the addition of methanol. 
The measured concentrations of BPA are shown in Table 18. Before analysis the pretreated sam-
ples were serially diluted in Milli-Q water to eliminate impact of methanol.  
The extraction of bisphenol A from other samples (not polycarbonate) was carried out by two 
methods. In the first method, used for the thermal receipt paper, 0.2 g of the thermal paper was 
inserted into 20 ml of ethanol and stirred for one hour at 35 °C [159]. The second method (taken 
from [160]) was used for flyers and magazines: 0.1 g of the sample was inserted into 2 ml of 
methanol and extracted in an ultrasonic bath at 35 °C for ten minutes. The samples were first 
filtered to remove the resulting dye coagulation and then cleaned with SPE as described below for 
LC-MS analysis. For the immunoassay, the solutions were filtrated and diluted in Milli-Q water.  
Solid-phase extraction (SPE)  
Real-world plastic samples represent a complex matrix which may contaminate or even clog in-
strumental analytical systems. For chromatographic analysis, a pre-treatment step had to be in-
serted after the extraction of bisphenol A, else the presence of interferences in the sample could 
result in instrument downtime due to a buildup of contamination with each injection into the LC-
MS. It was important to perform solid-phase extraction (SPE) of the samples. During this clean-
up, many disturbing substances that have a different polarity than bisphenol A, are removed from 
Destroy the surface of the 
polymer by scratching (1 g of  
sample)
Place the sample inside an 
erlenmeyer flask Add 30 ml of dichloromethane
Place the erlenmeyer flask in 
an ultrasonic bath at 25 °C for 
45 min
Add 70 ml of methanol 
(dropwise until precipitate of 
the polymer forms), let the 
precipitate settle
Filtrate through 0.45 μm filter 




the extract and thus cannot influence the measurement. The protocol of this SPE has been previ-
ously described [161, 162].  
As said, clean-up by SPE is indispensable for LC-MS and it is an expensive and extremely time-
consuming process. Immunoassays (LFIA, FPIA and ELISA) do not require SPE, which makes 
these assays especially cost-effective and fast.  
4.6.2. Analysis of polymer materials and products  
Samples were processed to obtain crude and purified extracts, then were analysed by LFIA, FPIA, 
ELISA, and LC-MS, respectively. The results are shown in Table 18.  
Table 18. Analytical result of selected samples (n = 3 replicates). The values of BPA found with 
LC-MS/MS, FPIA, ELISA, and LFIA are shown. Information in brackets indicates the recovery 
rate (BPA in relation to LC-MS/MS) of the immunoassays.  
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[μg/L] 
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Rubber duck toy 1.6±0.2 <LOD – <LOD – 1.5±0.2 
(93) 
17 
iPhone screen protector 1±0.3 <LOD – <LOD – 1.1±0.3 
(106) 
15 
Thermal receipt paper 
BE [163] 




Thermal receipt paper 
RU (Perekrestok) 





The FPIA, ELISA, LFIA results are in close agreement with each other. The satisfactory accuracy 
and precision of these methods suggests them to be sufficiently sensitive and reliable for the anal-
ysis of BPA in different type of samples.  
It was found by the LC-MS analysis, that the thermal paper samples contain high concentrations 
of BPS (270–779 μg/L) (Figure S 11). Considering the toxic potential of BPS and due to the lack 
of data on transfer rates of BPS from paper to skin, it is needed to investigate further the effects of 
this compound in the environment and on human health [25, 164]. 
  
Thermal receipt paper 
DE (Kaufland) 
<LOD <LOD – <LOD – <LOD – 






















Food contact papers <LOD <LOD – <LOD – <LOD – 
Ruhleben, influent <LOD <LOD – <LOD – <LOD – 
Schönerlinde, influent <LOD <LOD – <LOD – <LOD – 
Waßmannsdorf, influent <LOD <LOD – <LOD – <LOD – 
Ruhleben, effluent <LOD <LOD – <LOD – <LOD – 
Schönerlinde, effluent <LOD <LOD – <LOD – <LOD – 




V. CONCLUSIONS    
Three different techniques for the determination of the endocrine-disrupting compound bisphenol 
A in polymer materials were developed and compared, namely an easy-to-use Lateral Flow Im-
munoassay (LFIA), a mix-and-read Fluorescence Polarization Immunoassay (FPIA) and the high-
throughput indirect ELISA as reference method, which possess different advantages in terms of 
efficacity and convenience to be used on-site.  
An indirect competitive ELISA was developed and optimized, conjugates (BVA-BSA and BVA-
Ahx-BSA, derived from BVA, a linkable BPA mimic) were synthesized, one including a C6 spacer 
(Ahx). MALDI-TOF measurements showed the conjugation of BVA (bisphenol valeric acid) mol-
ecules to the BSA (bovine serum albumin) carrier protein and a spacer derivate of it (BSA-Ahx). 
Determined from the precision profile of the BPA calibration curve, the assay showed an LOD of 
0.05 μg/L and an IC50 of 0.2 μg/L. ELISAs are suitable tools for quick and sensitive analysis with 
high sample throughput. However, such techniques often require long reaction times and involve 
multiple washing steps and incubations, thus ELISA was the most time-consuming among the 
three formats.  
FPIA is a homogeneous mix-and-read method which does not require the immobilization of rea-
gents. Structurally different tracers (including one with a C6 spacer) to establish a fluorescence 
polarization immunoassay for BPA were synthesized and tested for the first time, and a rapid 
method was developed. The tracer molecules were assessed for performance and the FPIA for 
sensitivity. Full optimization of the assays was performed, studying the influence of the tracer 
structure on assay sensitivity, and the comparative assessment of performance was studied. FPIA 
displayed satisfactory precision and sensitivity with an IC50 of 7.5 μg/L and an LOD of 1.0 μg/L, 
which is sensitive compared to previously reported LODs. The FPIA method showed significant 
advantage in assay time, a sample measurement can be executed within 20 to 30 minutes. The 
satisfactory accuracy proved that the newly developed method is suitable to work as a rapid and 
inexpensive method for the detection of BPA.  
Lateral Flow Immunoassay (LFIA) is an assay without the need for expensive equipment, washing, 
and/or separation steps, used in clinical laboratories or at the point-of-care with minimal training. 
It has obtained a high degree of familiarity in the 2020/2021 COVID-19 pandemic and proved its 
invaluable meaning in on-site analysis. In this work, gold nanoparticles and latex microparticles 




direct physisorption and covalent attachment of the antibodies to the particles. Activity of bound 
antibodies was confirmed in both cases by a developed sandwich ELISA. Two solutions, one with 
latex microparticles and one with gold particles, with the same concentration results and the same 
surface coverage with antibody were obtained. The conjugate pad was selected from a huge variety 
of commercially available commodities and a blocking step was conceived and optimized. 
An important base, the nitrocellulose membrane, was selected from a large choice, each nitrocel-
lulose membrane having unique capillary flow characteristics based on the physical attributes of 
the membrane and the manufacturing process that impacts flow dynamics, sensitivity, specificity, 
and consistency of the assay. Non-contact spotting conditions, load of reagents per strip on the 
membrane (number of drops per spot, number of spots per line and number of lines), particle-
antibody conjugate loads as well as membrane stabilizing solutions influencing the assay perfor-
mance were investigated and optimized for the best color intensity. An additional membrane 
blocking step was selected and optimized.  
Under the optimal conditions, the latex-based LFIA allowed BPA to be visually detected at 10 
μg/L. Scanner-based quantification resulted in an LOD of 0.14 μg/L, respectively. To our 
knowledge, this is the first work reporting the development of a lateral-flow latex-based technique 
for the detection of BPA. Based on the results of this study, the described technique could be used 
for the fast and cost-effective determination of BPA. 
Cross-reactivity studies involving structurally related compounds like BVA, 4-CP, BPE, BPF, 
OCP, BPS, 4-NP showed high selectivity of the antibody to BPA, except for BPB which resembles 
much BVA the supposedly used hapten to obtain these antibodies. 
The quantification limits of LFIA, ELISA, and FPIA were far below the current Specific Migration 
Limit set for bisphenol A by the EU Commission (600 μg/L). Furthermore, the simplicity of all 
three immunoassays are clearly evidenced by their high sample throughput, since dozens of sam-
ples can be simultaneously analysed. So, they all are a promising technique for monitoring bi-









Figure S 1. MALDI-TOF/MS spectra of unconjugated BSA (present in the product) and BSA 
conjugated with BVA. It can be seen that the mean in the mass signal distribution of the conju-
gate has increased significantly compared to BSA. The spectrum represents the average of three 
measurement (n = 3).  
Figure S 2. Overlay of MALDI-TOF/MS spectra of unconjugated BSA [167] and BSA conju-
gated with BVA-Ahx (blue). It can be seen that the mean in the mass signal distribution of the 
conjugate has increased significantly compared to BSA. The spectrum represents the average of 
three measurements (n = 3). 
 





































Figure S 3. Chromatographic peak: verification of the reaction of BVA with Ahx with the largest 
signal at m/z (BVA-Ahx-H+) = 400.2. This reflects the mass of the desired product (399 g/mol) 
plus the mass of a proton (+1).
Table S 1. Rf values of the collected bands of the tracers during purification by TLC (each tracer 




















































Figure S 4. Synthesis of BVA-Ahx-AMF before TLC purification: 1. Total ion chromatogram 
[168] showing the same peaks as the diode array detector (DAD) chromatogram (chromatogram 
3) plus a major peak at RT = 16.2 min. 2. Mass spectrum of chromatographic peak at RT = 
16.174 min, with the largest signal at m/z = 741.1 Da. This reflects the mass of the desired 
product (742.3 g/mol) minus the mass of a proton (–1). 3. HPLC chromatogram, DAD trace, 
showing two larger signals at RT = 16.174 min and RT = 16.13 min. 4. Extracted Ion Chroma-












Figure S 5. Synthesis of BVA-Ahx-AMF after TLC purification: 1. Mass spectrum of chroma-
tographic peak at RT = 16.190 min, with the largest signal at m/z = 741.5 Da. This reflects the 
mass of the desired product (742.3 g/mol) minus the mass of a proton (–1). 2. HPLC chromato-
gram, DAD trace, showing larger signals at RT = 16.12 min. 3. TIC (total ion chromatogram) 
showing the same peaks as the DAD plus a major peak at RT = 18.24 min. 4. Extracted Ion 











Figure S 6. Synthesis of BVA-AMF. Characterization of the product before TLC purification: 1. 
TIC (total ion chromatogram) showing the same peaks as the DAD (trace 4) plus a major peak at 
RT = 15.12 min. 2. Extracted Ion Chromatogram (XIC, m/z = from 629 to 631) showing the peak 
of the desired product at 15.10 min. 3. Mass spectrum of the chromatographic peak at RT from 
15.091 to 15.282 min, with the largest signal at m/z = 630.2 Da. This reflects the mass of the 
desired product (629.3 g/mol) plus the mass of a proton (+1).  4. HPLC chromatogram, DAD trace, 










Figure S 7. Synthesis of BVA-AMF. Characterization of the product after TLC purification: 1. 
TIC (total ion chromatogram) showing the same peaks as the DAD (trace 4) plus a major peak at 
RT = 15.22 min. 2. Extracted Ion Chromatogram (XIC, m/z = from 630 to 631) showing the peak 
of the desired product at 15.85 min. 3. Mass spectrum of chromatographic peak at RT from 15.792 
to 15.897 min, with the largest signal at m/z = 630.3 Da. This reflects the mass of the desired 
product (629.3 g/mol) plus the mass of a proton (+1). 4. HPLC chromatogram, DAD trace, show-
ing a signal at RT = 15.15. 
TIC of +Q1: from Sample 1 (BVA-AMF, Syntheseprodukt Eremin) of 172303006.wiff (Turbo Spray IonDrive) Max. 4.8e9 cps.





2.15 15.22 21.8115.84 20.29 24.4118.7913.9613.52 28.9625.34 27.6123.074.91 11.462.90 10.859.441.05 7.08
XIC of +Q1: 630 to 631 Da from Sample 1 (BVA-AMF, Syntheseprodukt Eremin) of 172303006.wiff (Turbo Spray IonDrive) Max. 4.9e8 cps.






 +Q1: 15.792 to 15.897 min from Sample 1 (BVA-AMF, Syntheseprodukt Eremin) of 172303006.wiff (Turbo Spray IonDrive), subtracted (15.722 to 1... Max. 4.1e7 cps.







99.6 554.3 633.4297.2 452.2 493.3314.1226.0 670.4
TWC of DAD Spectral Data: from Sample 1 (BVA-AMF, Syntheseprodukt Eremin) of 172303006.wiff Max. 1.4e4 mAU.





























Concentration of protein, μg/mL
 
Figure S 8. Bradford assay standard curve of absorbance against protein concentration. 
 
S.2 Dot-Lateral Flow Immunoassay 
A Dot-LFIA is a simple and rapid technique for the determination of antibody-GNP and analyte 
conjugate binding [143, 169]. A schematic illustration of the one-dot LFIA is shown in Figure 
S 9. The key of the assay is using a pipette to apply the conjugate (T-spot) and a secondary anti-
body (C-spot) onto the NC membrane and identify the binding of the antibody-GNP in the test and 
control spot area. Once bound, the antibody and conjugate are visualized. A Dot-LFIA is able to 
provide information about the minimum concentration of conjugate needed for following the spot-
ting on an NC membrane by a non-contact spotter. This information will conveniently help to 
reduce the time needed for spotting optimization. Secondly, it will visualize the difference of NC 
membranes by measuring the optical density of the signal (Figure S 9) dependent on the concen-
tration of GNP.  
84
Figure S 9. Schematic of the Dot-LFIA
Protocol of the Dot-LFIA
First, one μL of the sheep anti-mouse-IgG (1 μg/mL) was applied on the NC membrane with a
pipette as a control spot. Next, one μL of BVA-Ahx-BSA solution with different concentration (5 
μg/mL, 10 μg/mL, 15 μg/mL) was applied as a test spot, then the membrane was dried for 25 min 
at room temperature. The NC membrane was blocked by immersion in 2 % Casein in PBS for 15 
minutes under continuous shaking at 150 rpm and subsequently washed three times with Milli-Q 
water (Figure S 9). Ultimately, the NC membrane was soaked with anti-BPA-IgG-GNP with 2 
OD. The concentration of 10 μg/mL BVA-Ahx-BSA was chosen for further optimization and the 
spotting step. 
Afterwards, different types of nitrocellulose membranes (NC) were tested and soaked with anti-
BPA-IgG-GNP with different optical densities (1, 2, 10, 20 OD) (Figure S 10) for 20 min and then 
washed in Milli-Q water. The intensity of the spot signals was determined by ImageJ. The NC 
with the most intensive signal was chosen for future optimization steps. 
To calculate the dilutions of anti-BPA-IgG-GNP, the following equation (a) was used, entering
the initial OD (OD1 = OD provided on the certificate of analysis or measured by UV-Vis spectros-
copy), the final OD2 , and the desired final volume (V2):
OD1 V1 = OD2 V2                                                     (a)
where OD corresponds to the optical density and V to the volume, respectively.  
85 
The specific binding reaction between the secondary antibody and GNP-primary antibody and 







Figure S 9. Typical photograph of the Dot-LFIA strips 
In this way, the color signal of GNPs can be enhanced since the most suitable nitrocellulose mem-
brane is chosen for the following spotting process. The membrane assay provided an intense signal 
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Table S 2. The specific interaction of the antibody-latex microparticles (IgG-LMP) and 
antibody-gold nanoparticles (IgG-GNP) probe on different types of membranes. 
Membrane type Microphoto images of interaction with anti-BPA mouse IgG 
– particles and coating conjugate BVA-Ahx-BSA
Merck Millipore Microphoto images of sin-
gle spot (IgG-GNP)
Microphoto images of line created 




















12 μm  
CNPF-SN12-L2-P25  
10 μm  
CNPC-SS12-L2-P25  































































































































































































































































































































A. Thermal receipt paper BE [163] 
 














D.  Thermal receipt paper RU  
 
E. Flyer DE 
Figure S 11. Chromatograms of BPA and BPS 1. XIC (extracted ion chromatogram) showing the peak 
of the desired BPA at 12.99 and BPS at 10.47 min. 2. XIC (extracted ion chromatogram) showing the 
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